B1k chain of laminin and methods of use

ABSTRACT

Antibodies directed against laiminin B1k are provided.

RELATED APPLICATIONS

[0001] This application is a continuation of U.S. application Ser. No. 10/443,349, filed May 22, 2003, which is a continuation of U.S. application Ser. No. 09/161,872, filed Sep. 28, 1998, which is a continuation of U.S. application Ser. No. 08/735,893, filed Oct. 23, 1996, now U.S. Pat. No. 5,914,317, which is a divisional of U.S. Ser. No. 08/144,121, filed on Oct. 27, 1993, now U.S. Pat. No. 5,610,031, the disclosures of which are incorporated herein by reference in their entirety.

GOVERNMENT SUPPORT

[0002] This invention was made with government support. The U.S. government may have certain rights in this invention.

BACKGROUND OF THE INVENTION

[0003] The present invention relates to adhesion proteins and to methods of using them, e.g., to promote the adhesion of cells to a substrate, e.g., to human dermis. In particular, overlapping cDNA clones encoding the entire laminin B1k chain and recombinant proteins expressed therefrom are disclosed.

[0004] The structure of the prototype laminin, a glycoprotein component of most, if not all, basement membranes has been well described in a number of species. Its overall appearance, as visualized by rotary shawdowing, is cross-shaped with a single long arm arising from the coiled-coil interaction of three separate polypeptide chains and three short arms, each originating from the individual polypeptide chains. The three chains are: A, typified by the Ae chain of EHS laminin (400-kD); B1, typified by the B1e chain of EHS laminin (220-kD); and B2, typified by the B2e chain of EHS laminin (210-kD) chains. The primary structure for each of the three prototypic polypeptide chains in humans has been elucidated by overlapping cDNAs.

[0005] Additional polypeptides that are related to the laminin chains have been identified. A rat B1 chain homologue, s-laminin (B1s), has been identified. A human A chain homologue, merosin (Am), has been described and is the same as a homologue A chain found in mouse and bovine heart. Both chains can combine with the laminin A, B1 or B2 chains to form the variant trimeric proteins [Ae, B1s, B2e], [Am, B1e, B2e] and [Am, B1s]. A second B1 variant (the sequence of which is a chain based on partial cDNA sequences) from avian eye has been reported and overlapping cDNAs for a human variant B2 chain called laminin B2t have also been described.

[0006] Kalinin is an epithelium-specific laminin variant that is the major, if not the only component of the anchoring filament. (The anchoring filament is a characteristic ultrastructural component of the dermal-epidermal junction of skin believed to mediate the adhesion of the epithelium to the basement membrane.) The kalinin molecule contains three disulfide bond-linked polypeptide chains consisting of a 200-kD kalinin A chain (Ak), a 155-kD kalinin B2 chain (B2t), and a 140-kD kalinin B1 chain (B1k). Rotary shadowing of the molecule results in a 107-nm rod with globular domains at each end.

[0007] Kalinin is an epithelial-specific cell attachment factor utilized by skin keratinocytes for strengthening their attachment to the underlying dermis. Antibodies to the Ak chain cause the detachment of subconfluent karatinocytes from their growth substrate and deepithelization of intact skin.

SUMMARY OF THE INVENTION

[0008] In general, the invention features a purified DNA including a sequence encoding a B1k chain of laminin.

[0009] In preferred embodiments: the DNA encodes the B1k protein of (SEQ ID NO:2); the encoded B1k peptide is at least 80, more preferably 90, and most preferably 95 or 98% homologous with the sequence of (SEQ ID NO:2); the DNA encodes a biologically active B1k.

[0010] In another aspect, the invention features a recombinant B1k.

[0011] In preferred embodiments: the recombinant B1k protein has the sequence of (SEQ ID NO:2); the recombinant B1k peptide is at least 80, more preferably 90, and most preferably 95 or 98% homologous with the sequence of (SEQ ID NO:2); the recombinant B1k has biological activity.

[0012] The invention also includes a vector including a DNA sequence encoding a B1k protein; a cell containing the vector; a method for manufacture of B1k including culturing the cell in a medium to express B1k.

[0013] In another aspect, the invention features a purified DNA including (or consisting essentially of) a sequence encoding a fragment of a B1k laminin chain.

[0014] In preferred embodiments: the sequence encodes domain VI of B1k, or a kalinin A chain-binding fragment thereof; the sequence encodes a peptide with a biological activity of domain VI of native B1k, e.g., the ability to bind to a kalinin A chain; the sequence encodes any of domain VI, V, IV, IV, III, α, or I of B1k.

[0015] In other preferred embodiments: the sequence of the encoded B1k fragment is essentially the same as that of a naturally occurring B1k sequence; the DNA sequence which encodes the B1k fragment is at least 85%, more preferably at least 90%, yet more preferably at least 95%, and most preferably at least 98 or 99% homologous with DNA encoding a naturally occurring B1k, e.g., B1k encoding DNA from SEQ ID NO:1; the sequence which encodes a B1k fragment hybridizes under high or low stringency to a nucleic acid which encodes a naturally occurring B1k sequence e.g., the amino acid sequence of SEQ ID NO:1; the amino acid sequence of the encoded B1k fragment is less than 30, more preferably less than 40, more preferably less than 50, and most preferably less than 60, 80, 100, or 200 amino acid residues in length; the encoded B1k amino acid sequence is at least 50% more preferably 60%, more preferably 70%, more preferably 80%, more preferably 90%, and most preferably 95% as long as a naturally occurring B1k; the amino acid sequence of the encoded B1k fragment is at least 80%, more preferably at least 85%, yet more preferably at least 90%, yet more preferably at least 95%, and a most preferably at least 98 or 99% homologous with a naturally occurring B1k sequence, e.g., the sequence of SEQ ID NO:1; the fragment has biological activity.

[0016] In other preferred embodiments the fragment includes more than one B1k domain and: the domains in the encoded peptide are arranged in the same relative linear order as found in a naturally B1k; the linear order of the encoded domains is different from that found in a naturally occurring B1k; the domains in the encoded peptide differ in one or more of composition (i.e., which domains are present), linear order, or number (i.e., how many domains are present or how many times a given domain is present) from a naturally occurring B1k.

[0017] In another aspect, the invention features, a DNA, preferably a purified DNA, which includes (or consists essentially of) a sequence encoding a fragment of B1k of 20 or more amino acids in length, the peptide having at least 90% homology with an amino acid sequence which is the same, or essentially the same, as a naturally occurring B1k peptide, e.g., the amino acid sequence of SEQ ID NO:2. In preferred embodiments the purified DNA encodes: a peptide which is at least 30, more preferably at least 40, more preferably at least 50, and most preferably at least 60, 80, 100, or 200, amino acid residues in length; the encoded peptide is at least 50% more preferably at least 60%, more preferably 70%, more preferably 80%, more preferably 90%, and most preferably 95% as long as a naturally occurring B1k; a peptide which is at least 80, more preferably at least 85, yet more preferably at least 90, yet more preferably at least 95, and most preferably at least 98 or 99% homologous with an amino acid sequence which is the same, or essentially the same, as a naturally occurring B1k peptide, e.g., the amino acid sequence of SEQ ID NO 2; the peptide has biological activity.

[0018] The invention also includes a DNA sequence encoding a B1k fragment; a cell containing the purified DNA; a method for manufacture of a B1k fragment comprising culturing the cell in a medium to express the B1k fragment.

[0019] In another aspect, the invention features a peptide which is a fragment of a B1k laminin chain.

[0020] In preferred embodiments: the peptide includes (or consists essentially of) domain VI of B1k or a kalinin A chain-binding fragment thereof; the peptide has a biological activity of domain VI of native B1k, e.g., the ability to bind to a kalinin A chain; the peptide includes any of domain VI, V, IV, III, II, α, or I of B1k; the fragment has biological activity.

[0021] In other preferred embodiments: the sequence of the peptide is essentially the same as that of a naturally occurring B1k sequence; the DNA sequence which encodes the B1k peptide is at least 85%, more preferably at least 90%, yet more preferably at least 95%, and most preferably at least 98 or 99% homologous with DNA encoding a naturally occurring B1k, e.g., B1k encoding DNA from SEQ ID NO:1; the sequence which encodes the B1k peptide hybridizes under high or low stringency to a nucleic acid which encodes a naturally occurring B1k sequence e.g., the amino acid sequence of SEQ ID NO:2; the amino acid sequence of the peptide is less than 30, more preferably less than 40, more preferably less than 50, and most preferably less than 60, 80, 100, or 200 amino acid residues in length; the peptide's amino acid sequence is at least 50% more preferably 60%, more preferably 70%, more preferably 80%, more preferably 90%, and most preferably 95% as long as a naturally occurring B1k; the amino acid sequence of the peptide is at least 80%, more preferably at least 85%, yet more preferably at least 90%, yet more preferably at least 95%, and a most preferably at least 98 or 99% homologous with a naturally occurring B1k sequence, e.g., the sequence of SEQ ID NO:2.

[0022] In other preferred embodiments the peptide includes more than one B1k domain and: the domains in the peptide are arranged in the same relative linear order as found in a naturally B1k; the linear order of the domains is different from that found in a naturally occurring B1k; the domains in the peptide differ in one or more of composition (i.e., which domains are present), linear order, or number (i.e., how many domains are present or how many times a given domain is present) from a naturally occurring B1k; the peptide has biological activity.

[0023] In another aspect, the invention features a transgenic animal, e.g., a rodent, having a B1k transgene, e.g., a transgene which misexpresses the B1k chain of laminin.

[0024] In another aspect, the invention features a method of increasing the permeability of the skin including inhibiting an interaction between B1k and a second molecule, e.g., a kalinin A chain.

[0025] In preferred embodiments, the interaction is inhibited by: administering an antibody against a site on kalinin A with which B1k interacts; administering an antibody against a site on B1k, e.g., a site in domain VI, which interacts with the second molecule; administering a fragment of B1k, e.g., a fragment containing domain VI which competes, e.g., competitively or non-competitively with B1k for a site on the second molecule.

[0026] In another aspect, the invention features a method of promoting the adhesion of a molecule, e.g., kalinin A or kalinin A-containing molecule, e.g., kalinin or laminin or a cell, e.g., a keratinocyte, to a substrate including providing the substrate coupled, linked, or adhered, to a fragment of B1k which includes domain VI, contacting the molecule or cell, with the B1k domain VI.

[0027] In preferred embodiments, the method further includes forming a covalent bond, e.g., a sulfhydral bond, between the molecule or cell and the B1k domain VI.

[0028] In another aspect, the invention features a peptide useful for promoting the adhesion of a first molecule or cell, e.g., a keratinocyte, to a second molecule or cell, e.g., a keratinocyte, including a first B1k domain linked to a second B1k domain. (The first domain, e.g., domain VI, binds to the first molecule or cell and the second domain, e.g., domain VI, binds to the second molecule or cell).

[0029] In another aspect, the invention features a method of coupling a first molecule or cell to a second molecule or cell including providing a molecule having a first B1k domain and a second B1k domain, linking the first molecule or cell to the first domain, and linking the second molecule or cell to the second domain.

[0030] In preferred embodiments: the first and/or second molecule is an adhesion molecule, e.g., laminin, kalinin, or collagen; the first and/or second B1k domain is domain VI or a kalinin A chain-binding fragment thereof of B1k; the first and/or second cell in a keratinocyte.

[0031] The invention also includes substantially pure preparation of an antibody, preferably a monoclonal antibody directed against a B1k protein or a fragment of a B1k protein, e.g., a fragment which contains only one domain of B1k; a therapeutic composition including an B1k protein or fragment thereof and a pharmaceutically acceptable carrier; a therapeutic composition which includes a purified DNA of the invention and a pharmaceutically acceptable carrier.

[0032] In another aspect, the invention features a method for treating an animal, e.g., a human, a mouse, a transgenic animal, or an animal model for a disorder, e.g., a disorder of the dermis, e.g., epidermal bulosis, including administering a therapeutically-effective amount of a B1k or fragment thereof to the animal.

[0033] In another aspect, the invention features a method for treating an animal, e.g., a human, a mouse, a transgenic animal, or an animal model for a disorder, e.g., a disorder of the dermis, e.g., epidermal bulosis, including administering to the animal cells selected, e.g., selected in vitro, for the expression of a product of the B1k gene, e.g., cells transformed with B1k or B1k fragment-encoding DNA.

[0034] In preferred embodiments: the cells are taken from the animal to which they are administered; the cells are taken from an animal which is MHC matched with the animal to which they are administered; the cells are taken from an animal which is syngeneic with the animal to which they are administered; the cells are taken from an animal which is of the same species as is the animal to which they are administered.

[0035] In another aspect, the invention features a method for treating an animal, e.g., a human, a mouse, a transgenic animal, or an animal model for a disorder, e.g., a disorder of the dermis, e.g, epidermal bulosis, including administering to the animal a nucleic acid encoding a B1k or fragment thereof and expressing the nucleic acid.

[0036] In another aspect, the invention features a method of evaluating the effect of a treatment, e.g., a treatment designed to promote adhesion of a keratinocyte to its substrate including carrying out the treatment and evaluating the effect of the treatment on the expression of the B1k gene.

[0037] In preferred embodiments the treatment is administered: to an animal, e.g., a human, a mouse, a transgenic animal, or an animal model for a dermal disorder, e.g., epidermal bulosis, or to a cell, e.g., a cultured cell.

[0038] In another aspect, the invention features a method for determining if a subject, e.g., a human, is at risk for a disorder related to mis-expression of the B1k gene, e.g., a disorder of the dermis, e.g., epidermal bulosis, including examining the subject for the expression of the B1k gene, non-wild type expression or mis-expression being indicative of risk.

[0039] In another aspect, the invention features a method for determining if a subject, e.g., a human, is at risk for a disorder related to mis-expression of the B1k gene, e.g., a disorder of the dermis, e.g., epidermal bulosis, including providing a nucleic acid sample from the subject and determining if the structure of an B1k gene allele of the subject differs from wild type.

[0040] In preferred embodiments: the determination includes determining if an B1k gene allele of the subject has a gross chromosomal rearrangement; the determination includes sequencing the subject's B1k gene.

[0041] In another aspect, the invention features, a method of evaluating an animal or cell model for a disorder, e.g., a disorder of the dermis, e.g., epidermal bulosis, including determining if the B1k gene in the animal or cell model is expressed at a predetermined level or if the B1k gene is mis-expressed. In preferred embodiments: the predetermined level is lower than the level in a wild type or normal animal; the predetermined level is higher than the level in a wild type or normal animal; or the pattern of isoform expression is altered from wildtype.

[0042] In another aspect, the invention features a transgenic rodent, e.g., a mouse, having a transgene which includes an B1k gene or B1k protein encoding DNA. In preferred embodiments: the B1k gene or DNA includes a deletion, e.g. a deletion of all or part of B1k, e.g., a deletion of all or part of a domain e.g., domain VI, or is otherwise mis-expressed.

[0043] Purified DNA is DNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (i.e., one at the 5′ end and one at the 3′ end) in the naturally occurring genome of the organism from which the DNA of the invention is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other DNA sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

[0044] Homologous refers to the degree of similarity in sequence between two polypeptide molecules or between two nucleic acid molecules. When a position in both of the two compared sequences is occupied by the same base or amino acid monomeric subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences. For example, 6 of 10, of the positions in two sequences are matched or homologous then the two sequences are 60% homologous. By way of example, the DNA sequences ATTGCC and TATGGC share 50% homology.

[0045] A transgene is defined as a piece of DNA which is inverted by artifice into a cell and becomes a part of the genome of the animal which develops in whole or part from that cell. Such a transgene may be partly or entirely heterologous to the transgenic animal.

[0046] A transgenic animal, e.g., a transgenic mouse, is an animal having cells that contain a transgene, which transgene was introduced into the animal, or an ancestor of the animal, at a prenatal, e.g., an embryonic stage.

[0047] A substantially pure preparation of a peptide is a preparation which is substantially free of the peptides with which it naturally occurs in a cell. A substantially pure preparation of a non-naturally occurring peptide is one which is at least 10% by weight of the peptide of interest.

[0048] Mis-expression, as used herein, refers to a non-wild type pattern of gene expression. It includes: expression at non-wild type levels, i.e., over or under expression; a pattern of expression that differs from wild type in terms of the time or stage at which the gene is expressed, e.g., increased or decreased expression (as compared with wild type) at a predetermined developmental period or stage; a pattern of expression that differs from wild-type in terms of the tissue specificity of expressions, e.g., increased or decreased expression (as compared with wild-type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild type in terms of the length, amino acid sequence, post-translational modification, or a biological activity of a B1k gene product; a patterns of expression that differs from wild-type in terms of the effect of an environmental stimulus or extracellular stimulus on expression of the gene, e.g., a pattern of increased or decreased expression (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus; or a pattern of isoform expression which differs from wild-type.

[0049] A protein or peptide has B1k biological activity if it has one or more of the following properties: the ability to covalently bind via disulfide bond formation with a kalinin B2 chain and a kalinin A chain to form a trimeric protein, kalinin; the ability to bind the kalinin A chain through a covalent disulfide bond formation with domain VI of the B1k chain; the ability to specifically bind type IV collagen; if a B1k domain present on a B1k protein or fragment has a biological property that the domain has when present in the native B1k molecule, e.g., the ability to bind or associate in a specific way with another molecule, e.g., another laminin or kalinin chain or the ability to form a characteristic native rotary shadowy structure characteristic of native B1k.

[0050] The molecules of the invention are useful for promoting adhesion of adhesion molecules or keratinocytes to a substrate, e.g., human dermis. The molecules of the invention are also useful for research in cell adhesion. The role of the DNA sequence encoding a peptide having B1k activity and its products can be studied in cells, e.g., cultured cells, transformed with the aforementioned DNA sequence, or fragments thereof, or in transgenic animals. The peptides fragments of the invention allow preparation of antibodies, i.e., monoclonal antibodies, directed against a specific domain.

[0051] Other features and advantages of the invention will be apparent from the following description and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0052]FIG. 1 is a map of the B1k region showing (heavy line) start (ATG) and stop codons (TGA), restriction sites (single letter abbreviations), and domains. The light lines below the map show overlapping cDNA clones encoding the entire kalinin B1 chain.

[0053]FIGS. 2-2C is a map of the nucleotide sequence of the laminin B1k chain (SEQ ID NO: 1) and the predicted amino acid sequence (SEQ ID NO: 2) of the B1k peptide chain. Triangles indicate potential N-linked glycosylation sites. Stars indicate potential glycosaminoglycan attachment sites. Potential O-linked glycosilation sites are underlined.

[0054]FIGS. 3A-3D, is a domain-by-domain comparison of the amino acid sequences of the laminin B1k chain (SEQ ID NO: 3) and the human B1 (SEQ ID NO: 4) chain (B1e).

[0055]FIG. 4 is: A) a comparison of the domain sizes and percent identity for the various domains of the laminin B1e and laminin B1k chains; and B) a depiction of the numbering scheme for the laminin B1k domains. The domains are numbered according to their similarity to the comparable domains in the laminin B1e chain. Some of the laminin B1e chain domains are missing in the laminin B1k chain and those that remain are truncated in comparison to the laminin B1e chain.

[0056]FIG. 5 is a comparison of the amino acid sequences of domain VI for B1k (SEQ ID NO: 5), B1e (SEQ ID NO: 6), and B1s (SEQ ID NO: 7). The underlined regions are areas where the sequence identity between B1e and B1s is above average, but the sequence identity with B1 is considerably less than average. The arrow shows an additional cysteine contained by B1k at residue number 50.

[0057]FIG. 6 is a comparison of peptide sequences of rat laminin B1s (SEQ ID NO: 8), human laminin B1s (SEQ ID NO: 9) and human laminin B1k (SEQ ID NO: 10). Also shown is a comparison of the amino acid sequences of human laminin B2t peptides determined by deduction from cDNA (SEQ ID NO: 11 and SEQ ID NO: 13) (top line) and from sequencing of purified peptide (bottom line) (SEQ ID NO: 12 and SEQ ID NO: 14).

[0058]FIG. 7 is a comparison of the cloned cDNA sequence to the B1 and B2 chains of laminin (LAMB1e and LAMB2e), the B2 chain of kalinin (LAMB2t) and the B1 chain of s-laminin (LAMB1s).

DETAILED DESCRIPTION

[0059] cDNA Clones for the Kalinin B1 (Laminin B1k) Chain

[0060] The screening of the squamous cell carcinoma cell cDNA expression library with a polyclonal antibody which recognizes human kalinin yielded several positive clones. The fusion proteins from positive clones were adsorbed to nitrocellulose and exposed to the polyclonal antiserum used for the initial screening. Antibodies binding the fusion proteins were individually collected and used for Western blot analysis of partially purified kalinin. Clones were identified that expressed fusion proteins that bound antibodies specific for the 140-kD and the 155/105-kD chain. (The B2 chain is processed from a 155 to a 105 kD form.) Selected clones were sequenced and the predicted amino acid sequences encoded by the cDNAs showed extensive homologies with the B1 and B2 laminin chains. The encoded sequences fro the B1k and B2t chains were confirmed by direct amino acid sequencing of the 140-kD and 155/105-kD kalinin chains.

[0061] The nucleotide sequences of the 155/105-kD chain were 99.9% identical to the recently published B2t chain and 100-kD chain of nicein. Protein sequencing of two tryptic peptides from the chain exactly matched derived amino acid sequences, confirming that laminin B2t, the 100-kD nicein chain and the 155/105-kD kalinin chain are identical.

[0062] Clones encoding the kalinin 140-kD kalinin B1 chain were selected for further characterization (Kal26, Kal45, Kal48, Kal68, Kal82, and Kal85, FIG. 1). These clones contained 1.5-kb, 0.9-kb, 1.3-kb, 1.8-kb, 1.2-kb, and 2.1-kb inserts, respectively, and nucleotide sequencing demonstrated that the derived amino acid sequences showed extensive similarity to human laminin B1 chain. Rescreening of the cDNA library with Kal45 resulted in the isolation of clones Kal5-5 and Kal6-4 (FIG. 1). These clones contained 2.3-kb and 1.0-kb inserts, respectively. To obtain the 3′ end of the cDNA, a 3′ RACE procedure (BRL) was used on total mRNA from squamous cell carcinoma media. This resulted in the clone Kal92-1 (1.8-kb). The complete nucleotide sequence of the overlapping clones and the predicted amino acid sequence are shown in FIG. 2.

[0063] The immunogen for polyclonal antiserum against kalinin purified from human keratinocyte-conditioned culture medium has been previously described (Lunstrum et al., 1986; Rousselle et al., 1991).

[0064] Isolation of RNA and cDNA synthesis were performed as follows. Ten Costar T-225 flasks were seeded with squamous carcinoma cells (SCC) and allowed to grow until sub-confluent. Media was removed and the cells were lysed and total RNA isolated following the guanidium thiocyanate method of Chomczynski and Sacchi, 1987. Poly A+RNA was collected using a Collaborative Research oligo dT Cellulose type 3 column and following company guidelines. Six hundred mg of Poly A+enriched RNA was sent to Clontech Laboratories (Palo Alto, Calif.) for construction of the Lambda gt11 cDNA library using random primers.

[0065] Library screening was performed as follows. The anti-kalinin polyclonal antibody (pAB) was diluted in 1:10 in 10 mM TNT (Tris-HCl, pH 8.0; 150 mM NaCl; 0.05% Tween 20; 3% BSA). E. coli (Y-1090 strain) whole cell lysate was added to the diluted antibody and incubated at 4° C. for 24 hours on a nutator. The pre-absorbed antibody was centrifuged at 10,000 rpm for 10 minutes at 4° C. and the supernatant collected. The absorbed antibody was then diluted 1:10 (final dilution 1:100) in TBST (50 mM Tris-HCl, pH 7.9; 150 mM NaCl; 0.05% Tween 20) and 1.2% BSA added. The diluted absorbed antibody was used to screen 8.34×10⁵ plaques from the unamplified random-primed cDNA library and horseradish peroxidase (HRP) secondary antibody was used to visualize the positive plaques. A total of 89 positive individual plaques were purified in a larger scale and tested again against the antibody.

[0066] Epitope determination for phage clones were performed as follows. For each clone, three 150×15 mm LB-ampicillin plates were plated at a density of 6000 pfu and grown 3 hours at 37° C. The plates were overlaid with IPTG saturated nitrocellulose filters and incubated overnight at 37° C. Plates were cooled at 4° C. for 15 minutes and the filters were removed and washed 3 times in TBST (15 min for each wash). The filters were blocked in 4% BSA in TBST for 1 hour at room temperature (RT). Filters were then washed 3 times in TBST. Filters were exposed to the pAB for 3-4 hours at RT followed by 3 washes in TBST. The antibody was eluted from the filter by soaking each filter in 25 ml of 1M acetic acid for 20 minutes. The antibody/acetic acid solution for each of the triplicate samples was pooled and 2 drops of a saturated phenol red solution was added. The solution was neutralized by the addition of an aqueous solution saturated with Tris-HCl and 0.03% BSA was added. The solution was dialyzed against two changes of 1×TBS at 4° C. overnight. The purified antibody solution was collected from the dialysis membrane and a “pinch” of BSA was added. The solution was frozen at −20° C. until needed.

[0067] Mini-western blots of purified kalinin were made and exposed to purified antibody from each of the clones for 60-hours at 4° C. Blots were then washed three times in TBST for 15 minutes each. Secondary HRP conjugated antibody was used to illuminate the particular band of kalinin chain corresponding to the clone.

[0068] Northern blots were performed as follows. Poly A+RNA was isolated from cell culture of 2 T165 flasks of 70-80% confluent squamous carcinoma cells using Invitrogen's Fast Track RNA isolation systems and exactly following the manufacturer's recommendations. The final RNA pellet was resuspended in 50 ml elution buffer. Twenty mb of Poly A+RNA was used for the gel and subsequent blot using the procedure outlined by Fourney et al. Clone Kal5-5 was radioactively labeled with the Amersham Random labeling system. The blot was placed against X-ray film for 2 hours at −80° C.

[0069] 3′ Rapid Amplification of cDNA Ends (RACE) was performed as follows. A 3′ RACE kit was purchased from GIBCO BRL and 1 mg poly A+RNA in 13 ml DEPC-treated water was made into cDNA by reverse transcriptase according to manufacturer's recommendations. The first strand DNA was amplified by PCR following the manufacturer's protocol using the provided antisense poly (T) primer called AP and a specific sense primer for the kalinin B1 chain called D92 (GCT TCA ATG GTC TCC TTA CTA TGT A) (SEQ ID NO: 15).

[0070] The Laminin B1k Chain Encodes a Distinct Laminin-Like Polypeptide

[0071] Analysis of the sequence showed that the first possible translated methionine (first amino acid residue, FIG. 2) is followed by a stretch of hydrophobic amino acid residues which are typical for a signal peptide. From the formula for a signal peptide (von Heijne, 1983 and 1986), the signal peptide would be cleaved following Ala17. The 17 residue long signal peptide is followed by an open reading frame of 1148 amino acid residues with a deduced molecular weight of 126,464 daltons. There are 3 putative N-linked glycosylation sites having the predicted residue sequence Asn-X-Ser/Thr, 3 potential O-linked glycosylation sites having the predicted cluster of three or more consecutive Ser and Thr residues and 2 potential glycosaminoglycan attachment consensus sequences, Ser-Gly-X-Gly. In addition there are 120 nucleotides of 5′ untranslated sequences and 315 nucleotides of 3′ untranslated sequences for a total of 3931 bases. Northern blot analysis showed a single message of 4.0-kb when probed with the cDNA clone Kal5-5.

[0072] Protein Sequencing was performed generally as according to Aebersold et al., 1987. Kalinin purified from amnion (Marinkovich et al., 1992a) was run on a polyacrylamide gel in the presence of 2-mercaptoethanol and blotted on a nitrocellulose membrane (Biorad). The 140-kD band was excised and digested by the protease Lys-C. The digested product was separated by HPLC and one fragment was sequenced on an Applied Biosystem sequencer. Computer analysis of the mature polypeptide demonstrated that the laminin B1k chain is most similar to the human laminin B1chain (LamB1E). A comparison of the laminin B1k polypeptide to this chain is presented in FIG. 3.

[0073] Pyroglutamate aminopeptidase reaction was performed generally as according to Andrews et al., 1991. Briefly, kalinin purified from amnion was run on a polyacrylamide gel in presence of 2-mercaptoethanol and blotted on a PVDF membrane in 25 mM Tris, 192 mM glycine, 0.05% SDS and 10% methanol for 4 hours. The 140-kD band was excised, blocked in PVP-40 in 0.1M acetic acid at 37° C. for 30 minutes, washed ten times in water and digested by pyro-glutamate aminopeptidase (Boehringer Mannheim) (62.5 mg/mg of protein in 50 mM sodium phosphate, 10 mM EDTA, SmM DTT, 5% glycerol, pH 8.0) for 12 hours at 4° C. An additional 62.5 mg of pyroglutamate aminopeptidase/mg of protein was added and digestion was done for 12 hours at 37° C. The blot was washed ten times in water, dried under vacuum and subjected to sequencing on an Applied Biosystem sequencer.

[0074] Domain Structure of the Laminin B1k Chain

[0075] Since the laminin B1k chain has similarity to the laminin B1e chain, its domains were assigned numbers according to their similarity to the comparable domains in laminin (FIG. 4A). Some of the laminin B1e chain domains are missing in the laminin B1k chain and those that remain are all truncated in comparison to the laminin B1e chain. Specifically, the carboxy-terminal ⅓ of domain V, all of domain IV, and the amino-terminal ⅔ of domain III are missing in the laminin B1k chain. FIG. 4A shows a comparison of the domain sizes and percent identity for the various domains of the laminin B1e and laminin B1k chains. The most amino-terminal domain, domain VI (residues 1-231), is a 231-amino acid residue region containing 9 cystine residues. This domain is likely to form a globular structure similar to domain VI in the laminin B1e chain. Domain III/V (residues 232-559) contains six cysteine-rich EGF modules with three of them similar to comparable modules in domain III (EGF 1, 2, and 3) and three of them similar to comparable modules in domain V (EGF 11, 12, 13) of the laminin B1e chain. The laminin B1k chain has no globular domain IV as is found the in the laminin B1e chain. Domain II (residues 560-766), as in the laminin B1e chain, begins with two closely spaced cysteins and is predicted to be an α-helical domain containing heptad repeats typical for coiled-coil proteins. Domain I (residues 798-1148) also contains heptad repeats typical for coiled-coil proteins. Just as in laminin B1e, this domain contains a single cysteine residue one residue away from the carobxyl-terminal end. Also similar to the laminin B1e chain is a cysteine-rich (6 cysteine residues) a domain that interrupts the helical structures of domains I and II.

[0076] Since domain VI is the only globular domain retained by the B1k chain, and since the homologous domain in laminin and s-laminin are believed to mediate self-assembly, the sequences of domain VI for B1k, B1e and B1s were compared (FIG. 5). The amino acid identity of domain VI for B1e and B1s shows 70% sequence conservation (FIG. 5). The number and location of cysteinyl residues is identical. Comparisons of the B1k sequence with these two chains shows 49.8% overall sequence identity. As shown in FIG. 5, B1e and B1s contain several regions within domain VI where the sequence identity is above average. Three of these regions share considerably less than average sequence identity with the B1k chain (FIG. 5, underlined). The B1k chain contains an additional cysteine at amino acid residue number 50 (FIG. 5, arrow). This region is also highly divergent from the B1e and B1s chains with an 18% amino acid residue identity to the B1e chain (excluding the obligatory cysteine) whereas, the same region is 70% identical between B1e and B1s. These comparisons suggest that B1k shares an overall structural similarity with B1e and B1s, but the chains are likely to be functionally divergent.

[0077] The Laminin B1k Chain Is a Truncated Chain

[0078] As described above, overlapping cDNA clones encoding the entire 140-kD laminin B1k chain were characterized. The 3.9-kb sequenced corresponds well with the 4.0-kb message size predicted by northern blot analysis. 3′ and 5′ RACE procedures and were not able to extend the sequence further on either end.

[0079] The identity of the cDNAs were confirmed by sequencing a 19-residue long tryptic peptide from the purified 140-kD laminin B1k chain (double-underlined in FIG. 2). Additional protein sequencing of the amino-terminal end of the polypeptide chain confirmed that the end was blocked and therefore most likely began with the residue Gln. After unblocking the end we determined the partial sequence Q-A-C—X—R (X is an indeterminate residue) which corresponds well with our predicted signal peptide cleavage site (start of domain VI, FIG. 2).

[0080] The estimated protein size from the cDNAs is 126,464 daltons. This is in contrast to protein data which predicts a protein of about 140,000 daltons. The most likely explanation for this discrepancy is that the chain is glycosylated. There are three potential N-linked glycosylation sites which are underlined in FIG. 2. There are two potential glycosaminoglycan attachment sites marked with stars and three potential N-linked glycosylation sites marked by triangle in FIG. 2. It is interesting to note that the three potential O-linked glycosylation sites are all located in the amino-terminal globular domain, domain VI, which rotary shadowed images predicts to project from the long arm, an ideal position to interact with other molecules such as carbohydrates. In addition, one N-linked glycosylation site is present in the α domain which may extend away from the long arm of the chain and interact with other molecules. The function of the α domain is not known.

[0081] The Laminin B1k Chain is Similar to the Laminin B1e and Laminin B1s Chains

[0082]FIG. 7 shows a comparison of our cDNA sequence to the B1 and B2 chains of laminin (LAMB1E and LAMB2E), the B2 chain of kalinin (LAMB2T) and the B1 chain of s-laminin (LAMB1S). Since the kalinin B1 chain is clearly related to these other laminin subunits, the convention of Engel et al., 1991 was followed and the Kalinin B1 chain will be named Laminin B1k. As is apparent from FIG. 7, the human laminin B1k chain is most similar to the human laminin B1e (34.1% identity) and rat laminin B1s (37.1% identity) chains. Initially it seemed possible that the laminin B1k chain might be the human equivalent of the laminin B1s chain since the amino acid residue identity was high when considering comparing two different species. There are two pieces of evidence that show that the laminin B1k chain is distinct from the laminin B1s chain. The first is the size of the laminin B1k chain polypeptide which was previously reported to be 140-kD. The laminin B1s chain in rat is about 190-kD which is only slightly smaller than the 200-kD laminin B1e chain. Since there is good conservation of protein size between species (from human to drosophila) for all three of the laminin chains (Laminin Ae, B1e, and B2e), one expects the same will hold true between species for the laminin B1s chain as well and it is predicted that this chain will be 190-200-kD in size. Additional evidence that the laminin B1k chain is distinct from the laminin B1s chain is the fact that a human tryptic peptide sequence was found that is not found in the laminin B1k chain, but has 95.8% identity to the rat laminin B1s chain.

[0083] Since the human sequence of the laminin B1s chain is not available, the B1k sequence was compared to the most well described similar molecule, the laminin B1e chain. The major difference between the laminin B1e and laminin B1k chains is their size. The laminin B1k chain has a truncated structure and, therefore, a lower molecular mass than the 200-kD laminin B1e chain. This smaller size is mainly due to the absence of the globular domain which corresponds to domain IV in the laminin B1e chain and to the fact that the corresponding domains III and V are fused into a single domain that is about half the size of the two domain together. There may also be differences in glycosylation between the two polypeptides.

[0084] As was found for the laminin B2t chain, the short arms of laminin B1k and laminin B1e have the greatest sequence homology than the long arms (FIG. 4, upper panel: compare domains III-VI, 40-50% identity, to domains I-II, 20-30% identity).

[0085] Domain Structure of the Short Arm of the Laminin B1k Chain

[0086] The greatest functional significance of the short arm is found in the amino-terminal domain VI. In laminin B1e, domain VI has been reported to aid in the self-assembly of the laminin molecules in vitro. The presence of this domain in the laminin B1k chain suggests that this domain could help to organize the extracellular matrix by associating with either other kalinin or laminin molecules. Since this domain is missing in laminin B2t, if the laminin protein associates with other molecules, then this domain is especially crucial in laminin B1k. One possible ligand for this domain is the recently described K-laminin molecule which contains the laminin B1e and B2e chains and a novel A chain. A second candidate for the interaction is type IV collagen which has been reported to bind to the short arms of the laminin B chains.

[0087] The comparison of the B1k sequence to B1e and B1s within the VI domain are particularly interesting. The highly divergent amino acid residue identity in certain areas (FIG. 5, underlined) strongly suggests that domain VI of B1k is functionally different from the other known laminin B1 chains. B1k domain VI also contains an odd number of cysteine residues (FIG. 6, arrow), suggesting that one of these is unpaired and available to stabilize interactions of domain VI with another entity. These observations support the hypothesis that kalinin is unlikely to self-assemble through interactions of the VI domains, but rather, the VI domain specifically interacts with the A chain of K-laminin. In tissues, kalinin is disulfide bonded to K-laminin, but not to other laminins that do not contain the K-laminin A chain. Rotary-shadowed images of the adduct suggest that the short arm region of kalinin associates at the crotch of the K-laminin short arms. Since the B1k chain is the only kalinin chain that remains unprocessed in the mature kalinin molecule, the association with K-laminin appears to be mediated by the B1k chain. The significant diversion in sequence homology between the VI domains of B1k versus B1e and B1s, and the presence of a potentially unpaired cysteine residue are consistent with the concept that the B1k VI domain binds the short arm of the K-laminin A chain enabling alignment of an unpaired cysteine in each molecule and subsequent disulfide bond formation.

[0088] Domain IV is missing in the laminin B1k chain and while no functions have been reported for the comparable domain in the laminin B1e chain, some investigators reported small peptide sequences in this area can bind to heparin. Since the entire domain is absent in kalinin these sequences are missing.

[0089] Two cell-surface binding peptide sequences (PDSGR and YIGSR) have been reported in the EGF repeat number 9 in domain III of the laminin B1e chain. These peptide sequences are not present since the EGF repeats numbered 6-10 are all missing in domain m of the laminin B1k chain.

[0090] Domain Structure of the Long Arm of the Kalinin B1 Chain

[0091] The long arm of the laminin B1k chain contains numerous heptad-repeats similar to those found in the two B chains of laminin. The laminin B1e and B2e chains have been found to associate with one another and are in fact disulfide-bonded. Clearly the three chains of kalinin are disulfide-bonded since they can only be separated by gel electrophoresis only after reduction by β-mercaptoethanol. The 155-kD kalinin chain is known to correspond to the previously reported truncated laminin B2t chain by the cDNAs discussed herein as well as to sequenced tryptic peptides (FIG. 7). The laminin B1k chain appears to interact with the laminin B2t chain by forming an α-helix as is found between the laminin B1e and B2e chains and in fact computer analysis predicts that laminin B1k can form an α-helical coiled-coil structure just as laminin B1e. The laminin B1k and the laminin B2t chain each have a single cysteine in their carboxy-terminal regions that are candidates for disulfide-bonding. The laminin B1k chain also has the short cysteine-rich α domain that divides domains I and II and is predicted to stick out from the long-arm and perform as yet unknown functions.

[0092] Finally, adhesion of ciliary ganglion neurons has been attributed to the specific sequence LRE in the laminin B1s chain. This sequence is not found in the laminin B1k chain and this function would therefore be missing.

OTHER EMBODIMENTS

[0093] Nucleic acid encoding all or part of the B1k chain can be used to transform cells. For example, the B1k gene, e.g., a mis-expressing or mutant form of the B1k gene, e.g., a deletion, or DNA encoding a B1k chain can be used to transform a cell and to produce a cell in which the cell's genomic B1k gene has been replaced by the transformed gene, producing, e.g., a cell deleted for the B1k gene. Such cells can be used with cells capable of being grown in culture, e.g., cultured stem cells, to investigate the function of the B1k gene.

[0094] Analogously, nucleic acid encoding all or part of the B1k gene, e.g., a mis-expressing or mutant form of the gene, e.g., a deletion, can be used to transform a cell which subsequently gives rise to a transgenic animal. This approach can be used to create, e.g., a transgenic animal in which the B1k gene is, e.g., inactivated, e.g., by a deletion. Homozygous transgenic animals can be made by crosses between the offspring of a founder transgenic animal. Cell or tissue cultures can be derived from a transgenic animal and the in vivo effects of the laminin B1k chain can subsequently be studied.

[0095] The invention includes any fragment of B1k, or any recombinantly produced B1k or fragment thereof which is substantially homologous to a B1k protein, e.g., the B1k protein shown in FIG. 2, or other isoforms. Also included are: allelic variations; natural mutants; induced mutants, e.g., in vitro deletions; proteins encoded by DNA that hybridizes under high or low (e.g., washing at 2×SSC at 40° C. with a probe length of at least 40 nucleotides) stringency conditions to a nucleic acid naturally occurring (for other definitions of high and low stringency see Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989, 6.3.1-6.3.6, hereby incorporated by reference); and polypeptides or proteins specifically bound by antisera to a B1k protein, especially by antisera to the active site or binding domain of a B1k protein. The term also includes chimeric polypeptides that include a B1k protein.

[0096] DNA and peptide sequences of the invention can be, e.g., mouse, primate, e.g., human, or non-naturally occurring sequences.

[0097] The invention also includes any biologically active fragment or analog of a B1k protein. By “biologically active” is meant possessing any in vivo or in vitro activity which is characteristic of B1k, e.g., B1k activity as described above. Because the B1k protein exhibits a range of physiological properties and because such properties may be attributable to different portions of the B1k protein molecule, a useful B1k protein fragment or B1k protein analog is one which exhibits a biological activity in any one (or more) of a variety of B1k protein assays, for example, the ability to bind the laminin Ak chain, as described above. A B1k protein fragment or analog possesses, most preferably 90%, preferably 40%, or at least 10%, of the activity of a naturally occurring B1k isoform, e.g., of the B1k protein shown in FIG. 2, in any in vivo or in vitro B1k assay.

[0098] Preferred analogs include B1k peptides or recombinant B1k proteins or peptides (or biologically active fragments thereof) whose sequences differ from the wild-type sequence by one or more conservative amino acid substitutions or by one or more non-conservative amino acid substitutions, deletions, or insertions which do not abolish biological activity. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g., substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Other conservative substitutions can be taken from the table below. CONSERVATIVE AMINO ACID REPLACEMENTS For Amino Acid Code Replace with any of Alanine A D-Ala, Gly, beta-Ala, L-Cys, D-Cys Arginine R D-Arg, Lys, D-Lys, homo-Arg, D- homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn Asparagine N D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln Aspartic Acid D D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln Cysteine C D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr Glutamine Q D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp Glutamic Acid E D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln Glycine G Ala, D-Ala, Pro, D-Pro, β-Ala Acp Isoleucine I D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met Leucine L D-Leu, Val, D-Val, Leu, D-Leu, Met, D-Met Lysine K D-Lys, Arg, D-Arg, homo-Arg, D- homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn Methionine M D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val Phenylalanine F D-Phe, Tyr, D-Thr, L-Dopa, His, D- His, Trp, D-Trp, Trans-3,4, or 5- phenylproline, cis-3,4, or 5-phenylproline Proline P D-Pro, L-I-thioazolidine-4- carboxylic acid, D- or L-1- oxazolidine-4-carboxylic acid Serine S D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L-Cys, D- Cys Threonine T D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Met(O), D-Met(O), Val, D-Val Tyrosine Y D-Tyr, Phe, D-Phe, L-Dopa, His, D- His Valine V D-Val, Leu, D-I, eu, Ile, D-Ile, Met, D-Met

[0099] Other useful modifications include those which increase peptide stability; such analogs may contain, for example, one or more non-peptide bonds (which replace peptide bonds) or D-amino acids in the peptide sequence.

[0100] Analogs can differ from a naturally occurring B1k protein in amino acid sequence or can modified in ways that do not affect sequence, or both. Analogs of the invention will generally exhibit at least 70%, more preferably 80%, more preferably 90%, and most preferably 95% or even, 99%, homology with a segment of 20 amino acid residues, preferably more than 40 amino acid residues or more preferably the entire sequence of naturally occurring B1k protein sequence.

[0101] Alterations in primary sequence include genetic variations, both natural and induced. Also included are analogs that include residues other than naturally occurring L-amino acids, e.g., D-amino acids or non-naturally occurring or synthetic amino acids, e.g., β or γ amino acids. Alternatively, increased stability may be conferred by cyclizing the peptide molecule.

[0102] Nonsequence modification include in vivo or in vitro chemical derivatization or polypeptides, e.g., acetylation, methylation, phosphorylation, carboxylation, or glycosylation; glycosylation can be modified, e.g., by modifying the glycosylation patterns of a polypeptide during its synthesis and processing or in further processing steps, e.g., by exposing the polypeptide to glycosylation-affecting enzymes derived from cells that normally provide such processing, e.g., mammalian glycosylation enzymes; phosphorylation can be modified by exposing the polypeptide to phosphorylation-altering enzymes, e.g., kinases or phosphatases.

[0103] Fragments of B1k proteins or peptides can be made by methods known to those skilled in the art, e.g., by expressing B1k DNA which has been manipulated in vitro to encode the desired fragment; e.g., by restriction digestion or other manipulation of a B1k DNA e.g., the sequence in FIG. 2. Analogs can be made by methods known to those skilled in the art, e.g., by in vitro DNA sequence modifications of the sequence of a B1k DNA e.g., the sequence in FIG. 2. For example, in vitro mutagenesis can be used to convert the DNA sequence of FIG. 2 into a sequence which encodes an analog in which one or more amino acid residues has undergone a replacement, e.g., a conservative replacement as described in the table of conservative amino acid substitutions provided herein. Fragments or analogs can be tested by methods known to those skilled in the art for the presence of B1k activity.

[0104] Also included are B1k protein polypeptides containing residues that are not required for biological activity of the peptide, such as residues that are not required for the biological activity of the polypeptide, or that result from alternative mRNA splicing or alternative protein processing events.

[0105] The invention also includes nucleic acids encoding the polypeptides of the invention.

[0106] In order to obtain a B1k protein, or fragment thereof, one can insert B1k-encoding DNA into an expression vector, introduce the vector into a cell suitable for expression of the desired protein, and recover and purify the desired protein by prior art methods. Antibodies to B1k proteins can be made by immunizing an animal, e.g., a rabbit or mouse, and recovering anti-B1k antibodies by prior art methods.

[0107] Other embodiments are within the following claims.

1 14 1 3931 DNA Homo sapiens CDS (122)..(3616) mat_peptide (173)..(3616) 1 gggcgtggag gaggactgta tctctggatg cctggggcct ggtttcaggg cctgatttat 60 tcctcttcct gggagctcac tcaggaaagg tcctttctgg ggatcacccc attggctgaa 120 g atg aga cca ttc ttc ctc ttg tgt ttt gcc ctg cct ggc ctc ctg cat 169 Met Arg Pro Phe Phe Leu Leu Cys Phe Ala Leu Pro Gly Leu Leu His -15 -10 -5 gcc caa caa gcc tgc tcc cgt ggg gcc tgc tat cca cct gtt ggg gac 217 Ala Gln Gln Ala Cys Ser Arg Gly Ala Cys Tyr Pro Pro Val Gly Asp -1 1 5 10 15 ctg ctt gtt ggg agg acc cgg ttt ctc cga gct tca tct acc tgt gga 265 Leu Leu Val Gly Arg Thr Arg Phe Leu Arg Ala Ser Ser Thr Cys Gly 20 25 30 ctg acc aag cct gag acc tac tgc acc cag tat ggc gag tgg cag atg 313 Leu Thr Lys Pro Glu Thr Tyr Cys Thr Gln Tyr Gly Glu Trp Gln Met 35 40 45 aaa tgc tgc aag tgt gac tcc agg cag cct cac aac tac tac agt cac 361 Lys Cys Cys Lys Cys Asp Ser Arg Gln Pro His Asn Tyr Tyr Ser His 50 55 60 cga gta gag aat gtg gct tca tcc tcc ggc ccc atg cgc tgg tgg cag 409 Arg Val Glu Asn Val Ala Ser Ser Ser Gly Pro Met Arg Trp Trp Gln 65 70 75 tcc cag aat gat gtg aac cct gtc tct ctg cag ctg gac ctg gac agg 457 Ser Gln Asn Asp Val Asn Pro Val Ser Leu Gln Leu Asp Leu Asp Arg 80 85 90 95 aga ttc cag ctt caa gaa gtc atg atg gag ttc cca ggg gcc cat gct 505 Arg Phe Gln Leu Gln Glu Val Met Met Glu Phe Pro Gly Ala His Ala 100 105 110 gcc ggc atg ctg att gag cgc tcc tca gac ttc ggt aag acc tgg cga 553 Ala Gly Met Leu Ile Glu Arg Ser Ser Asp Phe Gly Lys Thr Trp Arg 115 120 125 gtg tac cag tac ctg gct gcc gac tgc acc tcc acc ttc cct cgg gtc 601 Val Tyr Gln Tyr Leu Ala Ala Asp Cys Thr Ser Thr Phe Pro Arg Val 130 135 140 cgc cag ggt cgg cct cag agc tgg cag gat gtt cgg tgc cag tcc ctg 649 Arg Gln Gly Arg Pro Gln Ser Trp Gln Asp Val Arg Cys Gln Ser Leu 145 150 155 cct cag agg cct aat gca cgc cta aat ggg ggg aag gtc caa ctt aac 697 Pro Gln Arg Pro Asn Ala Arg Leu Asn Gly Gly Lys Val Gln Leu Asn 160 165 170 175 ctt atg gat tta gtg tct ggg att cca gca act caa agt caa aaa att 745 Leu Met Asp Leu Val Ser Gly Ile Pro Ala Thr Gln Ser Gln Lys Ile 180 185 190 caa gag gtg ggg gag atc aca aac ttg aga gtc aat ttc acc agg ctg 793 Gln Glu Val Gly Glu Ile Thr Asn Leu Arg Val Asn Phe Thr Arg Leu 195 200 205 gcc cct gtg ccc aaa ctg gac cac cct ccc agc gcc tac tat gct gtg 841 Ala Pro Val Pro Lys Leu Asp His Pro Pro Ser Ala Tyr Tyr Ala Val 210 215 220 tcc cag ctc cgt ctg cag ggg agc tgc ttc tgt cac ggc cat gct gat 889 Ser Gln Leu Arg Leu Gln Gly Ser Cys Phe Cys His Gly His Ala Asp 225 230 235 cgc tgc gca ccc aag cct ggg gcc tct gca ggc tcc acc gct gtg cag 937 Arg Cys Ala Pro Lys Pro Gly Ala Ser Ala Gly Ser Thr Ala Val Gln 240 245 250 255 gtc cac gat gtc tgc gtc tgc cag cac aac act gcc ggc cca aat tgt 985 Val His Asp Val Cys Val Cys Gln His Asn Thr Ala Gly Pro Asn Cys 260 265 270 gag cgc tgt gca ccc ttc tac aac aac cgg ccc tgg aga ccg gcg gag 1033 Glu Arg Cys Ala Pro Phe Tyr Asn Asn Arg Pro Trp Arg Pro Ala Glu 275 280 285 ggc cag gac gcc cat gaa tgc caa agg tgc gac tgc aat ggg cac tca 1081 Gly Gln Asp Ala His Glu Cys Gln Arg Cys Asp Cys Asn Gly His Ser 290 295 300 gag aac tgt cac ttt gac ccc gct gtg ttt gcc gcc agc cag ggg gca 1129 Glu Asn Cys His Phe Asp Pro Ala Val Phe Ala Ala Ser Gln Gly Ala 305 310 315 tat gga ggt gtg tgt gac aat tgc cgg gac cac acc gaa ggc aag aac 1177 Tyr Gly Gly Val Cys Asp Asn Cys Arg Asp His Thr Glu Gly Lys Asn 320 325 330 335 tgt gag cgg tgt cag ctg cac tat ttc cgg aac cgg cgc ccg gga gct 1225 Cys Glu Arg Cys Gln Leu His Tyr Phe Arg Asn Arg Arg Pro Gly Ala 340 345 350 tcc att cag gag acc tgc atc tcc tgc gag tgt gat ccg gat ggg cag 1273 Ser Ile Gln Glu Thr Cys Ile Ser Cys Glu Cys Asp Pro Asp Gly Gln 355 360 365 tgg gca ggg gct ccc tgt gac cca gtg acc ggg cag tgt gtg tgc aag 1321 Trp Ala Gly Ala Pro Cys Asp Pro Val Thr Gly Gln Cys Val Cys Lys 370 375 380 gag cat gtg cag gga gag cgc tgt gac cta tgc aag ccg ggc ttc act 1369 Glu His Val Gln Gly Glu Arg Cys Asp Leu Cys Lys Pro Gly Phe Thr 385 390 395 gga ctc acc tac gcc aac ccg cag ggc tgc cac cgc tgt gac tgc aac 1417 Gly Leu Thr Tyr Ala Asn Pro Gln Gly Cys His Arg Cys Asp Cys Asn 400 405 410 415 atc ctg ccc tcc cgg aga ctg ccg tgt gac gag gag agt ggg cgc tgc 1465 Ile Leu Pro Ser Arg Arg Leu Pro Cys Asp Glu Glu Ser Gly Arg Cys 420 425 430 ctt tgt ctg ccc aac gta ggt ggt ccc aaa tgt gac cag tgt gct ccc 1513 Leu Cys Leu Pro Asn Val Gly Gly Pro Lys Cys Asp Gln Cys Ala Pro 435 440 445 tac cac tgg aag ctg gcc agt ggc cag ggc tgt gaa ccg tgt gcc tgc 1561 Tyr His Trp Lys Leu Ala Ser Gly Gln Gly Cys Glu Pro Cys Ala Cys 450 455 460 gac ccg cac aac tcc ctc agc cca cag tgc aac cag ttc aca ggg cag 1609 Asp Pro His Asn Ser Leu Ser Pro Gln Cys Asn Gln Phe Thr Gly Gln 465 470 475 tgc ccc tgt cgg gaa ggc ttt ggt ggc ctg atg tgc agc gct gca gcc 1657 Cys Pro Cys Arg Glu Gly Phe Gly Gly Leu Met Cys Ser Ala Ala Ala 480 485 490 495 atc cgc cag tgt cca gac cgg acc tat gga gac gtg gcc aca gga tgc 1705 Ile Arg Gln Cys Pro Asp Arg Thr Tyr Gly Asp Val Ala Thr Gly Cys 500 505 510 cga gcc tgt gac tgt gat ttc cgg gga aca gag ggc ccg ggc tgc gac 1753 Arg Ala Cys Asp Cys Asp Phe Arg Gly Thr Glu Gly Pro Gly Cys Asp 515 520 525 aag gca tca ggc gtg ctc tgc cgc cct ggc ttg acc ggg ccc cgc tgt 1801 Lys Ala Ser Gly Val Leu Cys Arg Pro Gly Leu Thr Gly Pro Arg Cys 530 535 540 gac cag tgc cag cga ggc tac tgc aat cgc tac ccg gtg tgc gtg gcc 1849 Asp Gln Cys Gln Arg Gly Tyr Cys Asn Arg Tyr Pro Val Cys Val Ala 545 550 555 tgc cac cct tgc ttc cag acc tat gat gcg gac ctc cgg gag cag gcc 1897 Cys His Pro Cys Phe Gln Thr Tyr Asp Ala Asp Leu Arg Glu Gln Ala 560 565 570 575 ctg cgc ttt ggt aga ctc ccg aat gcc acc gcc agc ctg tgg tca ggg 1945 Leu Arg Phe Gly Arg Leu Pro Asn Ala Thr Ala Ser Leu Trp Ser Gly 580 585 590 cct ggg ctg gag gac cgt ggc ctg gcc tcc cgg atc cta gat gca aag 1993 Pro Gly Leu Glu Asp Arg Gly Leu Ala Ser Arg Ile Leu Asp Ala Lys 595 600 605 agt aag att gag cag atc cga gca gtt ctc agc agc ccc gca gtc aca 2041 Ser Lys Ile Glu Gln Ile Arg Ala Val Leu Ser Ser Pro Ala Val Thr 610 615 620 gag cag gag gtg gct cag gtg gcc agt gcc atc ctc tcc ctc agg cga 2089 Glu Gln Glu Val Ala Gln Val Ala Ser Ala Ile Leu Ser Leu Arg Arg 625 630 635 act ctc cag ggc ctg cag ctg gat ctg ccc ctg gag gag gag acg ttg 2137 Thr Leu Gln Gly Leu Gln Leu Asp Leu Pro Leu Glu Glu Glu Thr Leu 640 645 650 655 tcc ctt ccg aga gac ctg gag agt ctt gac aga agc ttc aat ggt ctc 2185 Ser Leu Pro Arg Asp Leu Glu Ser Leu Asp Arg Ser Phe Asn Gly Leu 660 665 670 ctt act atg tat cag agg aag agg gag cag ttt gaa aaa ata agc agt 2233 Leu Thr Met Tyr Gln Arg Lys Arg Glu Gln Phe Glu Lys Ile Ser Ser 675 680 685 gct gat cct tca gga gcc ttc cgg atg ctg agc aca gcc tac gag cag 2281 Ala Asp Pro Ser Gly Ala Phe Arg Met Leu Ser Thr Ala Tyr Glu Gln 690 695 700 tca gcc cag gct gct cag cag gtc tcc gac agc tcg cgc ctt ttg gac 2329 Ser Ala Gln Ala Ala Gln Gln Val Ser Asp Ser Ser Arg Leu Leu Asp 705 710 715 cag ctc agg gac agc cgg aga gag gca gag agg ctg gtg cgg cag gcg 2377 Gln Leu Arg Asp Ser Arg Arg Glu Ala Glu Arg Leu Val Arg Gln Ala 720 725 730 735 gga gga gga gga ggc acc ggc agc ccc aag ctt gtg gcc ctg agg ttg 2425 Gly Gly Gly Gly Gly Thr Gly Ser Pro Lys Leu Val Ala Leu Arg Leu 740 745 750 gag atg tct tcg ttg cct gac ctg aca ccc acc ttc aac aag ctc tgt 2473 Glu Met Ser Ser Leu Pro Asp Leu Thr Pro Thr Phe Asn Lys Leu Cys 755 760 765 ggc aac tcc agg cag atg gct tgc acc cca ata tca tgc cct ggt gag 2521 Gly Asn Ser Arg Gln Met Ala Cys Thr Pro Ile Ser Cys Pro Gly Glu 770 775 780 cta tgt ccc caa gac aat ggc aca gcc tgt gcg tcc cgc tgc agg ggt 2569 Leu Cys Pro Gln Asp Asn Gly Thr Ala Cys Ala Ser Arg Cys Arg Gly 785 790 795 gtc ctt ccc agg gcc ggt ggg gcc ttc ttg atg gcg ggg cag gtg gct 2617 Val Leu Pro Arg Ala Gly Gly Ala Phe Leu Met Ala Gly Gln Val Ala 800 805 810 815 gag cag ctg cgg gct tca atg cca gct cca gcg acc agg cag atg att 2665 Glu Gln Leu Arg Ala Ser Met Pro Ala Pro Ala Thr Arg Gln Met Ile 820 825 830 agg gca gcc gag gaa tct gcc tca cag att caa tcc agt gcc cag cgc 2713 Arg Ala Ala Glu Glu Ser Ala Ser Gln Ile Gln Ser Ser Ala Gln Arg 835 840 845 ttg gag acc cag gtg agc gcc agc cgc tcc cag atg gag gaa gat gtc 2761 Leu Glu Thr Gln Val Ser Ala Ser Arg Ser Gln Met Glu Glu Asp Val 850 855 860 aga cgc aca cgg ctc cta atc cag cag gtc cgg gac ttc cta aca gac 2809 Arg Arg Thr Arg Leu Leu Ile Gln Gln Val Arg Asp Phe Leu Thr Asp 865 870 875 ccc gac act gat gca gcc act atc cag gag gtc agg cga gcc gtg ctg 2857 Pro Asp Thr Asp Ala Ala Thr Ile Gln Glu Val Arg Arg Ala Val Leu 880 885 890 895 gcc ctg tgg ctg ccc aca gac tca gct act gtt ctg cag aag atg aat 2905 Ala Leu Trp Leu Pro Thr Asp Ser Ala Thr Val Leu Gln Lys Met Asn 900 905 910 gag atc cag gcc att gca gcc agg ctc ccc aac gtg gac ttg gtg ctg 2953 Glu Ile Gln Ala Ile Ala Ala Arg Leu Pro Asn Val Asp Leu Val Leu 915 920 925 tcc cag acc aag cag gac att ggc ggt gcc cgc cgg ttg cag gct gag 3001 Ser Gln Thr Lys Gln Asp Ile Gly Gly Ala Arg Arg Leu Gln Ala Glu 930 935 940 gct gag gaa gcc agg agc cga gcc cat gca gtg gag ggc cag gtg gag 3049 Ala Glu Glu Ala Arg Ser Arg Ala His Ala Val Glu Gly Gln Val Glu 945 950 955 gat gtg gtt ggg aac ctg cgg cag ggg aca gtg gca ctg cag gaa gct 3097 Asp Val Val Gly Asn Leu Arg Gln Gly Thr Val Ala Leu Gln Glu Ala 960 965 970 975 cag gac acc atg caa ggc acc agc cgg tcc ctt cgg ctt atc cag gac 3145 Gln Asp Thr Met Gln Gly Thr Ser Arg Ser Leu Arg Leu Ile Gln Asp 980 985 990 agg gtt gct gag gtt cag cag gta ctc ggc cag caa aag ctg gtg aca 3193 Arg Val Ala Glu Val Gln Gln Val Leu Gly Gln Gln Lys Leu Val Thr 995 1000 1005 agc atg acc aag cag ctg ggt gac ttc tgg aca cgg atg gag gag ctc 3241 Ser Met Thr Lys Gln Leu Gly Asp Phe Trp Thr Arg Met Glu Glu Leu 1010 1015 1020 cgc cac caa gcc cgg cag cag ggg gca gag gca gtc cag gcc cag cag 3289 Arg His Gln Ala Arg Gln Gln Gly Ala Glu Ala Val Gln Ala Gln Gln 1025 1030 1035 ctt gcg gaa ggt gcc agc gag cag gca ttg agt gcc caa gag gga ttt 3337 Leu Ala Glu Gly Ala Ser Glu Gln Ala Leu Ser Ala Gln Glu Gly Phe 1040 1045 1050 1055 gag aga ata aaa caa aag tat gct gag ttg aag gac cgg ttg ggt cag 3385 Glu Arg Ile Lys Gln Lys Tyr Ala Glu Leu Lys Asp Arg Leu Gly Gln 1060 1065 1070 agt tcc atg ctg ggt gag cag ggt gcc cgg atc cag agt gtg aag aca 3433 Ser Ser Met Leu Gly Glu Gln Gly Ala Arg Ile Gln Ser Val Lys Thr 1075 1080 1085 gag gca gag gag ctg ttt ggg gag acc atg gag atg atg gac agg atg 3481 Glu Ala Glu Glu Leu Phe Gly Glu Thr Met Glu Met Met Asp Arg Met 1090 1095 1100 aaa gac atg gag ttg gag ctg ctg cgg gca gca ggc cat cat gct gcg 3529 Lys Asp Met Glu Leu Glu Leu Leu Arg Ala Ala Gly His His Ala Ala 1105 1110 1115 ctc agc gac ctg aca gga ctg gag aag cgt gtg gag cag atc cgt gac 3577 Leu Ser Asp Leu Thr Gly Leu Glu Lys Arg Val Glu Gln Ile Arg Asp 1120 1125 1130 1135 cac atc aat ggg cgc gtg ctc tac tat gcc acc tgc aag tgatgctaca 3626 His Ile Asn Gly Arg Val Leu Tyr Tyr Ala Thr Cys Lys 1140 1145 cgttccagcc cgttgcccca ctcatctgcg cgctttgctt ttggttgggg ggcagattgg 3686 gttggaatgc tttccatctc caggagactt tcatgtagcc caaagtacag cctggaccac 3746 ccctggtgtg agtagctagt aagattaccc tgagctgcag ctgagcctga gccaatggga 3806 cagttacact tgacagacaa agatggtgga gattggcatg ccattgaaac taagagctct 3866 caagtcaagg aagctgggct gggcagtatc ccccgccttt agttctccac aaaaaaaaaa 3926 aaaaa 3931 2 1165 PRT Homo sapiens 2 Met Arg Pro Phe Phe Leu Leu Cys Phe Ala Leu Pro Gly Leu Leu His -15 -10 -5 Ala Gln Gln Ala Cys Ser Arg Gly Ala Cys Tyr Pro Pro Val Gly Asp -1 1 5 10 15 Leu Leu Val Gly Arg Thr Arg Phe Leu Arg Ala Ser Ser Thr Cys Gly 20 25 30 Leu Thr Lys Pro Glu Thr Tyr Cys Thr Gln Tyr Gly Glu Trp Gln Met 35 40 45 Lys Cys Cys Lys Cys Asp Ser Arg Gln Pro His Asn Tyr Tyr Ser His 50 55 60 Arg Val Glu Asn Val Ala Ser Ser Ser Gly Pro Met Arg Trp Trp Gln 65 70 75 Ser Gln Asn Asp Val Asn Pro Val Ser Leu Gln Leu Asp Leu Asp Arg 80 85 90 95 Arg Phe Gln Leu Gln Glu Val Met Met Glu Phe Pro Gly Ala His Ala 100 105 110 Ala Gly Met Leu Ile Glu Arg Ser Ser Asp Phe Gly Lys Thr Trp Arg 115 120 125 Val Tyr Gln Tyr Leu Ala Ala Asp Cys Thr Ser Thr Phe Pro Arg Val 130 135 140 Arg Gln Gly Arg Pro Gln Ser Trp Gln Asp Val Arg Cys Gln Ser Leu 145 150 155 Pro Gln Arg Pro Asn Ala Arg Leu Asn Gly Gly Lys Val Gln Leu Asn 160 165 170 175 Leu Met Asp Leu Val Ser Gly Ile Pro Ala Thr Gln Ser Gln Lys Ile 180 185 190 Gln Glu Val Gly Glu Ile Thr Asn Leu Arg Val Asn Phe Thr Arg Leu 195 200 205 Ala Pro Val Pro Lys Leu Asp His Pro Pro Ser Ala Tyr Tyr Ala Val 210 215 220 Ser Gln Leu Arg Leu Gln Gly Ser Cys Phe Cys His Gly His Ala Asp 225 230 235 Arg Cys Ala Pro Lys Pro Gly Ala Ser Ala Gly Ser Thr Ala Val Gln 240 245 250 255 Val His Asp Val Cys Val Cys Gln His Asn Thr Ala Gly Pro Asn Cys 260 265 270 Glu Arg Cys Ala Pro Phe Tyr Asn Asn Arg Pro Trp Arg Pro Ala Glu 275 280 285 Gly Gln Asp Ala His Glu Cys Gln Arg Cys Asp Cys Asn Gly His Ser 290 295 300 Glu Asn Cys His Phe Asp Pro Ala Val Phe Ala Ala Ser Gln Gly Ala 305 310 315 Tyr Gly Gly Val Cys Asp Asn Cys Arg Asp His Thr Glu Gly Lys Asn 320 325 330 335 Cys Glu Arg Cys Gln Leu His Tyr Phe Arg Asn Arg Arg Pro Gly Ala 340 345 350 Ser Ile Gln Glu Thr Cys Ile Ser Cys Glu Cys Asp Pro Asp Gly Gln 355 360 365 Trp Ala Gly Ala Pro Cys Asp Pro Val Thr Gly Gln Cys Val Cys Lys 370 375 380 Glu His Val Gln Gly Glu Arg Cys Asp Leu Cys Lys Pro Gly Phe Thr 385 390 395 Gly Leu Thr Tyr Ala Asn Pro Gln Gly Cys His Arg Cys Asp Cys Asn 400 405 410 415 Ile Leu Pro Ser Arg Arg Leu Pro Cys Asp Glu Glu Ser Gly Arg Cys 420 425 430 Leu Cys Leu Pro Asn Val Gly Gly Pro Lys Cys Asp Gln Cys Ala Pro 435 440 445 Tyr His Trp Lys Leu Ala Ser Gly Gln Gly Cys Glu Pro Cys Ala Cys 450 455 460 Asp Pro His Asn Ser Leu Ser Pro Gln Cys Asn Gln Phe Thr Gly Gln 465 470 475 Cys Pro Cys Arg Glu Gly Phe Gly Gly Leu Met Cys Ser Ala Ala Ala 480 485 490 495 Ile Arg Gln Cys Pro Asp Arg Thr Tyr Gly Asp Val Ala Thr Gly Cys 500 505 510 Arg Ala Cys Asp Cys Asp Phe Arg Gly Thr Glu Gly Pro Gly Cys Asp 515 520 525 Lys Ala Ser Gly Val Leu Cys Arg Pro Gly Leu Thr Gly Pro Arg Cys 530 535 540 Asp Gln Cys Gln Arg Gly Tyr Cys Asn Arg Tyr Pro Val Cys Val Ala 545 550 555 Cys His Pro Cys Phe Gln Thr Tyr Asp Ala Asp Leu Arg Glu Gln Ala 560 565 570 575 Leu Arg Phe Gly Arg Leu Pro Asn Ala Thr Ala Ser Leu Trp Ser Gly 580 585 590 Pro Gly Leu Glu Asp Arg Gly Leu Ala Ser Arg Ile Leu Asp Ala Lys 595 600 605 Ser Lys Ile Glu Gln Ile Arg Ala Val Leu Ser Ser Pro Ala Val Thr 610 615 620 Glu Gln Glu Val Ala Gln Val Ala Ser Ala Ile Leu Ser Leu Arg Arg 625 630 635 Thr Leu Gln Gly Leu Gln Leu Asp Leu Pro Leu Glu Glu Glu Thr Leu 640 645 650 655 Ser Leu Pro Arg Asp Leu Glu Ser Leu Asp Arg Ser Phe Asn Gly Leu 660 665 670 Leu Thr Met Tyr Gln Arg Lys Arg Glu Gln Phe Glu Lys Ile Ser Ser 675 680 685 Ala Asp Pro Ser Gly Ala Phe Arg Met Leu Ser Thr Ala Tyr Glu Gln 690 695 700 Ser Ala Gln Ala Ala Gln Gln Val Ser Asp Ser Ser Arg Leu Leu Asp 705 710 715 Gln Leu Arg Asp Ser Arg Arg Glu Ala Glu Arg Leu Val Arg Gln Ala 720 725 730 735 Gly Gly Gly Gly Gly Thr Gly Ser Pro Lys Leu Val Ala Leu Arg Leu 740 745 750 Glu Met Ser Ser Leu Pro Asp Leu Thr Pro Thr Phe Asn Lys Leu Cys 755 760 765 Gly Asn Ser Arg Gln Met Ala Cys Thr Pro Ile Ser Cys Pro Gly Glu 770 775 780 Leu Cys Pro Gln Asp Asn Gly Thr Ala Cys Ala Ser Arg Cys Arg Gly 785 790 795 Val Leu Pro Arg Ala Gly Gly Ala Phe Leu Met Ala Gly Gln Val Ala 800 805 810 815 Glu Gln Leu Arg Ala Ser Met Pro Ala Pro Ala Thr Arg Gln Met Ile 820 825 830 Arg Ala Ala Glu Glu Ser Ala Ser Gln Ile Gln Ser Ser Ala Gln Arg 835 840 845 Leu Glu Thr Gln Val Ser Ala Ser Arg Ser Gln Met Glu Glu Asp Val 850 855 860 Arg Arg Thr Arg Leu Leu Ile Gln Gln Val Arg Asp Phe Leu Thr Asp 865 870 875 Pro Asp Thr Asp Ala Ala Thr Ile Gln Glu Val Arg Arg Ala Val Leu 880 885 890 895 Ala Leu Trp Leu Pro Thr Asp Ser Ala Thr Val Leu Gln Lys Met Asn 900 905 910 Glu Ile Gln Ala Ile Ala Ala Arg Leu Pro Asn Val Asp Leu Val Leu 915 920 925 Ser Gln Thr Lys Gln Asp Ile Gly Gly Ala Arg Arg Leu Gln Ala Glu 930 935 940 Ala Glu Glu Ala Arg Ser Arg Ala His Ala Val Glu Gly Gln Val Glu 945 950 955 Asp Val Val Gly Asn Leu Arg Gln Gly Thr Val Ala Leu Gln Glu Ala 960 965 970 975 Gln Asp Thr Met Gln Gly Thr Ser Arg Ser Leu Arg Leu Ile Gln Asp 980 985 990 Arg Val Ala Glu Val Gln Gln Val Leu Gly Gln Gln Lys Leu Val Thr 995 1000 1005 Ser Met Thr Lys Gln Leu Gly Asp Phe Trp Thr Arg Met Glu Glu Leu 1010 1015 1020 Arg His Gln Ala Arg Gln Gln Gly Ala Glu Ala Val Gln Ala Gln Gln 1025 1030 1035 Leu Ala Glu Gly Ala Ser Glu Gln Ala Leu Ser Ala Gln Glu Gly Phe 1040 1045 1050 1055 Glu Arg Ile Lys Gln Lys Tyr Ala Glu Leu Lys Asp Arg Leu Gly Gln 1060 1065 1070 Ser Ser Met Leu Gly Glu Gln Gly Ala Arg Ile Gln Ser Val Lys Thr 1075 1080 1085 Glu Ala Glu Glu Leu Phe Gly Glu Thr Met Glu Met Met Asp Arg Met 1090 1095 1100 Lys Asp Met Glu Leu Glu Leu Leu Arg Ala Ala Gly His His Ala Ala 1105 1110 1115 Leu Ser Asp Leu Thr Gly Leu Glu Lys Arg Val Glu Gln Ile Arg Asp 1120 1125 1130 1135 His Ile Asn Gly Arg Val Leu Tyr Tyr Ala Thr Cys Lys 1140 1145 3 1147 PRT Artificial Sequence DOMAIN (1)...(231) Laminin B1k chain 3 Gln Gln Ala Cys Ser Arg Gly Ala Cys Tyr Pro Pro Val Gly Asp Leu 1 5 10 15 Leu Val Gly Arg Thr Arg Phe Leu Arg Ala Ser Ser Thr Cys Gly Leu 20 25 30 Thr Lys Pro Glu Thr Tyr Cys Thr Gln Tyr Gly Glu Trp Gln Met Lys 35 40 45 Cys Cys Lys Cys Asp Ser Arg Gln Pro His Asn Tyr Tyr Ser His Arg 50 55 60 Val Glu Asn Val Ala Ser Ser Ser Gly Pro Met Arg Trp Trp Gln Ser 65 70 75 80 Gln Asn Asp Val Asn Pro Val Ser Leu Gln Leu Asp Leu Asp Arg Arg 85 90 95 Phe Gln Leu Gln Glu Val Met Met Glu Phe Pro Gly Ala His Ala Ala 100 105 110 Gly Met Leu Ile Glu Arg Ser Ser Asp Phe Gly Lys Thr Trp Arg Val 115 120 125 Tyr Gln Tyr Leu Ala Ala Asp Cys Thr Ser Thr Phe Pro Arg Val Arg 130 135 140 Gln Gly Arg Pro Gln Ser Trp Gln Asp Val Arg Cys Gln Ser Leu Pro 145 150 155 160 Gln Arg Pro Asn Ala Arg Leu Asn Gly Gly Lys Val Gln Leu Asn Leu 165 170 175 Met Asp Leu Val Ser Gly Ile Pro Ala Thr Gln Ser Gln Lys Ile Gln 180 185 190 Glu Val Gly Glu Ile Thr Asn Leu Arg Val Asn Phe Thr Arg Leu Ala 195 200 205 Pro Val Pro Lys Leu Asp His Pro Pro Ser Ala Tyr Tyr Ala Val Ser 210 215 220 Gln Leu Arg Leu Gln Gly Ser Cys Phe Cys His Gly His Ala Asp Arg 225 230 235 240 Cys Ala Pro Lys Pro Gly Ala Ser Ala Gly Ser Thr Ala Val Gln Val 245 250 255 His Asp Val Cys Val Cys Gln His Asn Thr Ala Gly Pro Asn Cys Glu 260 265 270 Arg Cys Ala Pro Phe Tyr Asn Asn Arg Pro Trp Arg Pro Ala Glu Gly 275 280 285 Gln Asp Ala His Glu Cys Gln Arg Cys Asp Cys Asn Gly His Ser Glu 290 295 300 Asn Cys His Phe Asp Pro Ala Val Phe Ala Ala Ser Gln Gly Ala Tyr 305 310 315 320 Gly Gly Val Cys Asp Asn Cys Arg Asp His Thr Glu Gly Lys Asn Cys 325 330 335 Glu Arg Cys Gln Leu His Tyr Phe Arg Asn Arg Arg Pro Gly Ala Ser 340 345 350 Ile Gln Glu Thr Cys Ile Ser Cys Glu Cys Asp Pro Asp Gly Gln Trp 355 360 365 Ala Gly Ala Pro Cys Asp Pro Val Thr Gly Gln Cys Val Cys Lys Glu 370 375 380 His Val Gln Gly Glu Arg Cys Asp Leu Cys Lys Pro Gly Phe Thr Gly 385 390 395 400 Leu Thr Tyr Ala Asn Pro Gln Gly Cys His Arg Cys Asp Cys Asn Ile 405 410 415 Leu Pro Ser Arg Arg Leu Pro Cys Asp Glu Glu Ser Gly Arg Cys Leu 420 425 430 Cys Leu Pro Asn Val Gly Gly Pro Lys Cys Asp Gln Cys Ala Pro Tyr 435 440 445 His Trp Lys Leu Ala Ser Gly Gln Gly Cys Glu Pro Cys Ala Cys Asp 450 455 460 Pro His Asn Ser Leu Ser Pro Gln Cys Asn Gln Phe Thr Gly Gln Cys 465 470 475 480 Pro Cys Arg Glu Gly Phe Gly Gly Leu Met Cys Ser Ala Ala Ala Ile 485 490 495 Arg Gln Cys Pro Asp Arg Thr Tyr Gly Asp Val Ala Thr Gly Cys Arg 500 505 510 Ala Cys Asp Cys Asp Phe Arg Gly Thr Glu Gly Pro Gly Cys Asp Lys 515 520 525 Ala Ser Gly Val Leu Cys Arg Pro Gly Leu Thr Gly Pro Arg Cys Asp 530 535 540 Gln Cys Arg Gly Tyr Cys Asn Arg Tyr Pro Val Cys Val Ala Cys His 545 550 555 560 Pro Cys Phe Gln Thr Tyr Asp Ala Asp Leu Arg Glu Gln Ala Leu Arg 565 570 575 Phe Gly Arg Leu Pro Asn Ala Thr Ala Ser Leu Trp Ser Gly Pro Gly 580 585 590 Leu Glu Asp Arg Gly Leu Ala Ser Arg Ile Leu Asp Ala Lys Ser Lys 595 600 605 Ile Glu Gln Ile Arg Ala Val Leu Ser Ser Pro Ala Val Thr Glu Gln 610 615 620 Glu Val Ala Gln Val Ala Ser Ala Ile Leu Ser Leu Arg Arg Thr Leu 625 630 635 640 Gln Gly Leu Gln Leu Asp Leu Pro Leu Glu Glu Glu Thr Leu Ser Leu 645 650 655 Pro Arg Asp Leu Glu Ser Leu Asp Arg Ser Phe Asn Gly Leu Leu Thr 660 665 670 Met Tyr Gln Arg Lys Arg Glu Gln Phe Glu Lys Ile Ser Ser Ala Asp 675 680 685 Pro Ser Gly Ala Phe Arg Met Leu Ser Thr Ala Tyr Glu Gln Ser Ala 690 695 700 Gln Ala Ala Gln Gln Val Ser Asp Ser Ser Arg Leu Leu Asp Gln Leu 705 710 715 720 Arg Asp Ser Arg Arg Glu Ala Glu Arg Leu Val Arg Gln Ala Gly Gly 725 730 735 Gly Gly Gly Thr Gly Ser Pro Lys Leu Val Ala Leu Arg Leu Glu Met 740 745 750 Ser Ser Leu Pro Asp Leu Thr Pro Thr Phe Asn Lys Leu Cys Gly Asn 755 760 765 Ser Arg Gln Met Ala Cys Thr Pro Ile Ser Cys Pro Gly Glu Leu Cys 770 775 780 Pro Gln Asp Asn Gly Thr Ala Cys Ala Ser Arg Cys Arg Gly Val Leu 785 790 795 800 Pro Arg Ala Gly Gly Ala Phe Leu Met Ala Gly Gln Val Ala Glu Gln 805 810 815 Leu Arg Ala Ser Met Pro Ala Pro Ala Thr Arg Gln Met Ile Arg Ala 820 825 830 Ala Glu Glu Ser Ala Ser Gln Ile Gln Ser Ser Ala Gln Arg Leu Glu 835 840 845 Thr Gln Val Ser Ala Ser Arg Ser Gln Met Glu Glu Asp Val Arg Arg 850 855 860 Thr Arg Leu Leu Ile Gln Gln Val Arg Asp Phe Leu Thr Asp Pro Asp 865 870 875 880 Thr Asp Ala Ala Thr Ile Gln Glu Val Arg Arg Ala Val Leu Ala Leu 885 890 895 Trp Leu Pro Thr Asp Ser Ala Thr Val Leu Gln Lys Met Asn Glu Ile 900 905 910 Gln Ala Ile Ala Ala Arg Leu Pro Asn Val Asp Leu Val Leu Ser Gln 915 920 925 Thr Lys Gln Asp Ile Gly Gly Ala Arg Arg Leu Gln Ala Glu Ala Glu 930 935 940 Glu Ala Arg Ser Arg Ala His Ala Val Glu Gly Gln Val Glu Asp Val 945 950 955 960 Val Gly Asn Leu Arg Gln Gly Thr Val Ala Leu Gln Glu Ala Gln Asp 965 970 975 Thr Met Gln Gly Thr Ser Arg Ser Leu Arg Leu Ile Gln Asp Arg Val 980 985 990 Ala Glu Val Gln Gln Val Leu Gly Gln Gln Lys Leu Val Thr Ser Met 995 1000 1005 Thr Lys Gln Leu Gly Asp Phe Trp Thr Arg Met Glu Glu Leu Arg His 1010 1015 1020 Gln Ala Arg Gln Gln Gly Ala Glu Ala Val Gln Ala Gln Gln Leu Ala 1025 1030 1035 1040 Glu Gly Ala Ser Glu Gln Ala Leu Ser Ala Gln Glu Gly Phe Glu Arg 1045 1050 1055 Ile Lys Gln Lys Tyr Ala Glu Leu Lys Asp Arg Leu Gly Gln Ser Ser 1060 1065 1070 Met Leu Gly Glu Gln Gly Ala Arg Ile Gln Ser Val Lys Thr Glu Ala 1075 1080 1085 Glu Glu Leu Phe Gly Glu Thr Met Glu Met Met Asp Arg Met Lys Asp 1090 1095 1100 Met Glu Leu Glu Leu Leu Arg Ala Ala Gly His His Ala Ala Leu Ser 1105 1110 1115 1120 Asp Leu Thr Gly Leu Glu Lys Arg Val Glu Gln Ile Arg Asp His Ile 1125 1130 1135 Asn Gly Arg Val Leu Tyr Tyr Ser Thr Cys Lys 1140 1145 4 1196 PRT Artificial Sequence DOMAIN (1)...(250) Human B1 chain 4 Gln Glu Pro Glu Phe Ser Tyr Gly Cys Ala Glu Gly Ser Cys Tyr Pro 1 5 10 15 Ala Thr Gly Asp Leu Leu Ile Gly Arg Ala Gln Lys Leu Ser Val Thr 20 25 30 Ser Thr Thr Cys Gly Leu His Lys Pro Glu Pro Tyr Cys Ile Val Ser 35 40 45 His Leu Gln Glu Asp Lys Lys Cys Phe Ile Cys Asn Ser Gln Asp Pro 50 55 60 Tyr His Glu Thr Leu Asn Pro Asp Ser His Leu Ile Glu Asn Val Val 65 70 75 80 Thr Thr Phe Ala Pro Asn Arg Leu Lys Ile Trp Trp Gln Ser Glu Asn 85 90 95 Gly Val Glu Asn Val Thr Ile Gln Leu Asp Leu Glu Ala Glu Phe His 100 105 110 Phe Thr His Leu Ile Met Thr Phe Lys Thr Phe Arg Pro Ala Ala Met 115 120 125 Leu Ile Glu Arg Ser Ser Asp Phe Gly Lys Thr Trp Gly Val Tyr Arg 130 135 140 Tyr Phe Ala Tyr Asp Cys Glu Ala Ser Phe Pro Gly Ile Ser Thr Gly 145 150 155 160 Pro Met Lys Lys Val Asp Asp Ile Ile Cys Asp Ser Arg Tyr Ser Asp 165 170 175 Ile Glu Pro Ser Thr Glu Gly Glu Val Ile Phe Arg Ala Leu Asp Pro 180 185 190 Ala Phe Lys Ile Glu Asp Pro Tyr Ser Pro Arg Ile Gln Asn Leu Leu 195 200 205 Lys Ile Thr Asn Leu Arg Ile Lys Phe Val Lys Leu His Thr Leu Gly 210 215 220 Asp Asn Leu Leu Asp Ser Arg Met Glu Ile Arg Glu Lys Tyr Tyr Tyr 225 230 235 240 Ala Val Tyr Asp Met Val Val Arg Gly Asn Cys Phe Cys Tyr Gly His 245 250 255 Ala Ser Glu Cys Ala Pro Val Asp Gly Phe Asn Glu Glu Val Glu Gly 260 265 270 Met Val His Gly His Cys Met Cys Arg His Asn Thr Lys Gly Leu Asn 275 280 285 Cys Gly Leu Cys Met Asp Phe Tyr His Asp Leu Pro Trp Arg Pro Ala 290 295 300 Glu Gly Arg Asn Ser Asn Ala Cys Lys Lys Cys Asn Cys Asn Glu His 305 310 315 320 Ser Ile Ser Cys His Phe Asp Met Ala Val Tyr Leu Ala Thr Gly Asn 325 330 335 Val Ser Gly Gly Val Cys Asp Asp Cys Gln His Asn Thr Met Gly Arg 340 345 350 Asn Cys Glu Gln Cys Lys Pro Phe Tyr Tyr Gln His Pro Glu Arg Asp 355 360 365 Ile Arg Asp Pro Asn Phe Cys Glu Arg Cys Thr Cys Asp Pro Ala Gly 370 375 380 Ser Gln Asn Glu Gly Ile Cys Asp Ser Tyr Thr Asp Phe Ser Thr Gly 385 390 395 400 Leu Ile Ala Gly Gln Cys Arg Cys Lys Leu Asn Val Glu Gly Glu His 405 410 415 Cys Asp Val Cys Lys Glu Gly Phe Tyr Asp Leu Ser Ser Glu Asp Pro 420 425 430 Phe Gly Cys Lys Ser Cys Val Cys Asn Tyr Leu Gly Thr Val Gln Glu 435 440 445 His Cys Asn Gly Ser Asp Cys Gln Cys Asp Lys Ala Thr Gly Gln Cys 450 455 460 Leu Cys Leu Pro Asn Val Ile Gly Gln Asn Cys Asp Arg Cys Ala Pro 465 470 475 480 Asn Thr Trp Gln Leu Ala Ser Gly Thr Gly Cys Asp Pro Cys Asn Cys 485 490 495 Asn Ala Ala His Ser Phe Gly Pro Ser Cys Asn Glu Phe Thr Gly Gln 500 505 510 Cys Gln Cys Met Pro Gly Phe Gly Gly Arg Thr Cys Ser Glu Cys Gln 515 520 525 Glu Leu Phe Trp Gly Asp Pro Asp Val Glu Cys Arg Ala Cys Asp Cys 530 535 540 Asp Pro Arg Gly Ile Glu Thr Pro Gln Cys Asp Gln Ser Thr Gly Gln 545 550 555 560 Cys Val Cys Val Glu Gly Val Glu Gly Pro Arg Cys Asp Lys Cys Thr 565 570 575 Arg Gly Tyr Ser Gly Val Phe Pro Asp Cys Thr Pro Cys His Gln Cys 580 585 590 Phe Ala Leu Trp Asp Val Ile Ile Ala Glu Leu Thr Asn Arg Thr His 595 600 605 Arg Phe Leu Glu Lys Ala Lys Ala Leu Lys Ile Ser Gly Val Ile Gly 610 615 620 Pro Tyr Arg Glu Thr Val Asp Ser Val Glu Arg Lys Val Ser Glu Ile 625 630 635 640 Lys Asp Ile Leu Ala Gln Ser Pro Ala Ala Glu Pro Leu Lys Asn Ile 645 650 655 Gly Asn Leu Phe Glu Glu Ala Glu Lys Leu Ile Lys Asp Val Thr Glu 660 665 670 Met Met Ala Gln Val Glu Val Lys Leu Ser Asp Thr Thr Ser Gln Ser 675 680 685 Asn Ser Thr Ala Lys Glu Leu Asp Ser Leu Gln Thr Glu Ala Glu Ser 690 695 700 Leu Asp Asn Thr Val Lys Glu Leu Ala Glu Gln Leu Glu Phe Ile Lys 705 710 715 720 Asn Ser Asp Ile Arg Gly Ala Leu Asp Ser Ile Thr Lys Tyr Phe Gln 725 730 735 Met Ser Leu Glu Ala Glu Glu Arg Val Asn Ala Ser Thr Thr Glu Pro 740 745 750 Asn Ser Thr Val Glu Gln Ser Ala Leu Met Arg Asp Arg Val Glu Asp 755 760 765 Val Met Met Glu Arg Glu Ser Gln Phe Lys Glu Lys Gln Glu Glu Gln 770 775 780 Ala Arg Leu Leu Asp Glu Leu Ala Gly Lys Leu Gln Ser Leu Asp Leu 785 790 795 800 Ser Ala Ala Ala Glu Met Thr Cys Gly Thr Pro Pro Gly Ala Ser Cys 805 810 815 Ser Glu Thr Glu Cys Gly Gly Pro Asn Cys Arg Thr Asp Glu Gly Glu 820 825 830 Arg Lys Cys Gly Gly Pro Gly Cys Gly Gly Leu Val Thr Val Ala His 835 840 845 Asn Ala Trp Gln Lys Ala Met Asp Leu Asp Gln Asp Val Leu Ser Ala 850 855 860 Leu Ala Glu Val Glu Gln Leu Ser Lys Met Val Ser Glu Ala Lys Leu 865 870 875 880 Arg Ala Asp Glu Ala Lys Gln Ser Ala Glu Asp Ile Leu Leu Lys Thr 885 890 895 Asn Ala Thr Lys Glu Lys Met Asp Lys Ser Asn Glu Glu Leu Arg Asn 900 905 910 Leu Ile Lys Gln Ile Arg Asn Phe Leu Thr Gln Asp Ser Ala Asp Leu 915 920 925 Asp Ser Ile Glu Ala Val Ala Asn Glu Val Leu Lys Met Glu Met Pro 930 935 940 Ser Thr Pro Gln Gln Leu Gln Asn Leu Thr Glu Asp Ile Arg Glu Arg 945 950 955 960 Val Glu Ser Leu Ser Gln Val Glu Val Ile Leu Gln His Ser Ala Ala 965 970 975 Asp Ile Ala Arg Ala Glu Met Leu Leu Glu Glu Ala Lys Arg Ala Ser 980 985 990 Lys Ser Ala Thr Asp Val Lys Val Thr Ala Asp Met Val Lys Glu Ala 995 1000 1005 Leu Glu Glu Ala Glu Lys Ala Gln Val Ala Ala Glu Lys Ala Ile Lys 1010 1015 1020 Gln Ala Asp Glu Asp Ile Gln Gly Thr Gln Asn Leu Leu Thr Ser Ile 1025 1030 1035 1040 Glu Ser Glu Thr Ala Ala Ser Glu Glu Thr Leu Phe Asn Ala Ser Gln 1045 1050 1055 Arg Ile Ser Glu Leu Glu Arg Asn Val Glu Glu Leu Lys Arg Lys Ala 1060 1065 1070 Ala Gln Asn Ser Gly Glu Ala Glu Tyr Ile Glu Lys Val Val Tyr Thr 1075 1080 1085 Val Lys Gln Ser Ala Glu Asp Val Lys Lys Thr Leu Asp Gly Glu Leu 1090 1095 1100 Asp Glu Lys Tyr Lys Lys Val Glu Asn Leu Ile Ala Lys Lys Thr Glu 1105 1110 1115 1120 Glu Ser Ala Asp Ala Arg Arg Lys Ala Glu Met Leu Gln Asn Glu Ala 1125 1130 1135 Lys Thr Leu Leu Ala Gln Ala Asn Ser Lys Leu Gln Leu Leu Lys Asp 1140 1145 1150 Leu Glu Arg Lys Tyr Glu Asp Asn Gln Arg Tyr Leu Glu Asp Lys Ala 1155 1160 1165 Gln Glu Leu Ala Arg Leu Glu Gly Glu Val Arg Ser Leu Leu Lys Asp 1170 1175 1180 Ile Ser Gln Lys Val Ala Val Tyr Ser Thr Cys Leu 1185 1190 1195 5 231 PRT Artificial Sequence DOMAIN (1)...(231) VI of B1k 5 Gln Gln Ala Cys Ser Arg Gly Ala Cys Tyr Pro Pro Val Gly Asp Leu 1 5 10 15 Leu Val Gly Arg Thr Arg Phe Leu Arg Ala Ser Ser Thr Cys Gly Leu 20 25 30 Thr Lys Pro Glu Thr Tyr Cys Thr Gln Tyr Gly Glu Trp Gln Met Lys 35 40 45 Cys Cys Lys Cys Asn Ser Arg Gln Pro His Asn Tyr Tyr Ser His Arg 50 55 60 Val Glu Asn Val Ala Ser Ser Ser Gly Pro Met Arg Trp Trp Gln Ser 65 70 75 80 Gln Asn Asp Val Asn Pro Val Ser Leu Gln Leu Asp Leu Asp Arg Arg 85 90 95 Phe Gln Leu Gln Glu Val Met Met Glu Phe Pro Gly Ala His Ala Ala 100 105 110 Gly Met Leu Ile Glu Arg Ser Ser Asp Phe Gly Lys Thr Trp Arg Val 115 120 125 Tyr Gln Tyr Leu Ala Ala Asp Cys Thr Ser Thr Phe Pro Arg Val Arg 130 135 140 Gln Gly Arg Pro Gln Ser Trp Gln Asp Val Arg Cys Gln Ser Leu Pro 145 150 155 160 Gln Arg Pro Asn Ala Arg Leu Asn Gly Gly Lys Val Gln Leu Asn Leu 165 170 175 Met Asp Leu Val Ser Gly Ile Glu Ala Thr Gln Ser Gln Lys Ile Gln 180 185 190 Glu Val Gly Glu Ile Thr Asn Leu Arg Ile Lys Phe Val Lys Leu Ala 195 200 205 Pro Val Pro Lys Leu Asp His Pro Pro Ser Ala Tyr Tyr Ala Val Ser 210 215 220 Gln Leu Arg Leu Gln Gly Ser 225 230 6 249 PRT Artificial Sequence DOMAIN (1)...(249) VI of B1e 6 Gln Glu Pro Glu Phe Ser Tyr Gly Cys Ala Glu Gly Ser Cys Tyr Pro 1 5 10 15 Ala Thr Gly Asp Leu Leu Ile Gly Arg Ala Gln Lys Leu Ser Val Thr 20 25 30 Ser Thr Cys Gly Leu His Lys Pro Glu Pro Tyr Cys Ile Val Ser His 35 40 45 Leu Gln Glu Asp Lys Lys Cys Phe Ile Cys Asn Ser Gln Asp Pro Tyr 50 55 60 His Glu Thr Leu Asn Pro Asp Ser His Leu Ile Glu Asn Val Val Thr 65 70 75 80 Thr Phe Ala Pro Asn Arg Leu Lys Ile Trp Trp Gln Ser Glu Asn Gly 85 90 95 Val Glu Asn Val Thr Ile Gln Leu Asp Leu Glu Ala Glu Phe His Phe 100 105 110 Thr His Leu Ile Met Thr Phe Lys Thr Phe Arg Pro Ala Ala Met Leu 115 120 125 Ile Glu Arg Ser Ser Asp Phe Gly Lys Thr Trp Gly Val Tyr Arg Tyr 130 135 140 Phe Ala Tyr Asp Cys Glu Ala Ser Phe Pro Gly Ile Ser Thr Gly Pro 145 150 155 160 Met Lys Lys Val Asp Asp Ile Ile Cys Asp Ser Arg Tyr Ser Asp Ile 165 170 175 Glu Pro Ser Thr Glu Gly Glu Val Ile Phe Arg Ala Leu Asp Pro Ala 180 185 190 Phe Lys Ile Glu Asp Pro Tyr Ser Pro Arg Ile Gln Asn Leu Leu Lys 195 200 205 Ile Thr Asn Leu Arg Ile Lys Phe Val Lys Leu His Thr Leu Gly Asp 210 215 220 Asn Leu Leu Asp Ser Arg Met Glu Ile Arg Glu Lys Tyr Tyr Tyr Ala 225 230 235 240 Val Tyr Asp Met Val Val Arg Gly Asn 245 7 250 PRT Artificial Sequence DOMAIN (1)...(250) VI of B1g 7 Gln Val Pro Ser Leu Asp Val Pro Gly Cys Ser Arg Gly Ser Cys Tyr 1 5 10 15 Pro Ala Thr Gly Asp Leu Leu Val Gly Arg Ala Asp Arg Leu Thr Ala 20 25 30 Ser Ser Thr Cys Gly Leu His Ser Pro Gln Pro Tyr Cys Ile Val Ser 35 40 45 His Leu Gln Asp Glu Lys Lys Cys Phe Leu Cys Asp Ser Arg Arg Pro 50 55 60 Phe Ser Ala Arg Asp Asn Pro Asn Ser His Arg Ile Gln Asn Val Val 65 70 75 80 Thr Ser Phe Ala Pro Gln Arg Arg Thr Ala Trp Trp Gln Ser Glu Asn 85 90 95 Gly Val Pro Met Val Thr Ile Gln Leu Asp Leu Glu Ala Glu Phe His 100 105 110 Phe Thr His Leu Ile Met Thr Phe Lys Thr Phe Arg Pro Ala Ala Met 115 120 125 Leu Val Glu Arg Ser Ala Asp Phe Gly Arg Thr Trp Arg Val Tyr Arg 130 135 140 Tyr Phe Ser Tyr Asp Cys Gly Ala Asp Phe Pro Gly Ile Pro Leu Ala 145 150 155 160 Pro Pro Arg Arg Trp Asp Asp Val Val Cys Glu Ser Arg Tyr Ser Glu 165 170 175 Ile Glu Pro Ser Thr Glu Gly Glu Val Ile Tyr Arg Val Leu Asp Pro 180 185 190 Ala Ile Pro Ile Pro Asp Pro Tyr Ser Ser Arg Ile Gln Asn Leu Leu 195 200 205 Lys Ile Thr Asn Leu Arg Val Asn Leu Thr Arg Leu His Thr Leu Gly 210 215 220 Asp Asn Leu Leu Asp Pro Arg Arg Glu Ile Arg Glu Lys Tyr Tyr Tyr 225 230 235 240 Ala Leu Tyr Glu Leu Val Ile Arg Gly Asn 245 250 8 40 PRT Rattus rattus 8 Glu Ala Leu Lys Leu Lys Arg Ala Gly Asn Ser Leu Ala Ala Ser Thr 1 5 10 15 Ala Glu Glu Thr Ala Gly Ser Ala Gln Ser Arg Ala Arg Glu Ala Glu 20 25 30 Lys Gln Leu Arg Glu Gln Val Gly 35 40 9 24 PRT Homo sapiens 9 Ala Gly Asn Ser Leu Ala Ala Ser Thr Ala Glu Glu Thr Ala Gly Ser 1 5 10 15 Ala Gln Gly Arg Ala Gln Glu Ala 20 10 40 PRT Homo sapiens 10 Glu Glu Leu Arg His Gln Ala Arg Gln Gln Gly Ala Glu Ala Val Gln 1 5 10 15 Ala Gln Gln Leu Ala Glu Gly Ala Ser Glu Gln Ala Leu Ser Ala Gln 20 25 30 Glu Gly Phe Glu Arg Ile Lys Gln 35 40 11 40 PRT Homo sapiens 11 Thr Gly Asp Cys Tyr Ser Gly Asp Glu Asn Pro Asp Ile Glu Cys Ala 1 5 10 15 Asp Cys Pro Ile Gly Phe Tyr Asn Asp Pro His Asp Pro Arg Ser Cys 20 25 30 Lys Pro Cys Pro Cys His Asn Gly 35 40 12 17 PRT Homo sapiens 12 Asp Glu Asn Pro Asp Ile Glu Cys Ala Asp Cys Pro Ile Gly Phe Tyr 1 5 10 15 Asn 13 40 PRT Homo sapiens 13 Lys Val Asp Thr Arg Ala Lys Asn Ala Gly Val Thr Ile Gln Asp Thr 1 5 10 15 Leu Asn Thr Leu Asp Gly Leu Leu His Leu Met Asp Gln Pro Leu Ser 20 25 30 Val Asp Glu Glu Gly Leu Val Leu 35 40 14 25 PRT Homo sapiens 14 Asn Ala Gly Val Thr Ile Gln Asp Thr Leu Asn Thr Leu Asp Gly Leu 1 5 10 15 Leu His Leu Met Asp Gln Pro Leu Ser 20 25 

What is claimed is:
 1. An isolated monoclonal antibody that binds to a polypeptide that consists of an amino acid sequence selected from the group consisting of: (a) domain VI of B1k, (b) domain III of B1k, (c) domain II of B1k, (d) domain I of B1k, (e) domain alpha of B1k, (f) any one of EGF domains 2, 3, 4, 5 or 6 of B1k and (g) any combination of (a)-(f).
 2. The monoclonal antibody of claim 1 wherein the antibody binds to (a).
 3. The monoclonal antibody of claim 1 wherein the antibody binds to (b).
 4. The monoclonal antibody of claim 1 wherein the antibody binds to (c).
 5. The monoclonal antibody of claim 1 wherein the antibody binds to (d).
 6. The monoclonal antibody of claim 1 wherein the antibody binds to (e).
 7. The monoclonal antibody of claim 1 wherein the antibody binds to (f). 8 The monoclonal antibody of any one of claims 1-7 wherein the antibody is a mouse monoclonal antibody.
 9. A composition comprising an antibody according to any one of claims 1-7 and a pharmaceutically acceptable carrier.
 10. A pharmaceutical composition comprising an antibody according to claim 8 and a pharmaceutically acceptable carrier.
 11. A pharmaceutical composition comprising an antibody according to claim 9 and a pharmaceutically acceptable carrier.
 12. A method for making a domain-specific antibody, the method comprising: immunizing an experimental animal with an immunogen comprising an isolated polypeptide that consists of an amino acid sequence selected from the group consisting of: (a) domain VI of B1k, (b) domain III/V of B1k, (c) domain II of B1k, (d) domain I of B1k, (e) domain alpha of B1k, (f) any one of EGF domains 1, 2, 3, 4, 5 or 6 of B1k, (g) immunogenic fragments of any of the foregoing, and (h) any combination of (a)-(g); and preparing, from the experimental animal, an antibody that binds to the immunogen.
 13. The method of claim 12, wherein the immunogen is a polypeptide consisting of domain VI of B1k or an immunogenic fragment thereof.
 14. The method of claim 12, wherein the immunogen is a polypeptide consisting of domain III/V of B1k or an immunogenic fragment thereof.
 15. The method of claim 12, wherein the immunogen is a polypeptide consisting of domain II of B1k or an antigenic fragment thereof.
 16. The method of claim 12, wherein the immunogen is a polypeptide consisting of domain I of B1k or an antigenic fragment thereof.
 17. The method of claim 12, wherein the immunogen is a polypeptide consisting of domain α of B1k or an antigenic fragment thereof.
 18. The method of claim 12, wherein the immunogen is a polypeptide consisting of any one of EGF domains 1, 2, 3, 4, 5 or 6 of B1k or an antigenic fragment thereof.
 19. The method of any one of claims 12-18, wherein the animal is a mouse.
 20. The method of any one of claims 12-18, wherein the antibody is a monoclonal antibody. 